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 i 
 
Abstract 
 
The cyanobacterial strain Microcystis species CAWBG11 was investigated in 
order to isolate and characterise bioactive oligopeptides such as aeruginosins 
and microviridins. 
 
Liquid Chromatography tandem Mass Spectrometry (LC-MS/MS) Analysis of 
a methanol extract of a Microcystis CAWBG11 identified four known 
aeruginosin variants and four putatively new aeruginosin congeners as 
aeruginosins 618, 656A, 656B and 602B. Planar structures for these new 
congeners were proposed based on the MS/MS data, in conjunction with the 
sequence of the known aeruginosins. 
 
Amongst the aeruginosins detected there were three pairs, each with the same 
molecular masses but exhibiting different retention times. Each pair was 
assigned as stereoisomers since they yielded identical tandem mass fragment 
ions. 
 
The previously reported aeruginosin 602A was further characterised using the 
Advanced Marfey’s Method of amino acid analysis and Nuclear Magnetic 
Resonance (NMR) spectroscopy. 
 
Four new congeners of the cyclic microviridins; 1778A, 1778B, 1760 and 1764 
were detected from a methanol extract of Microcystis CAWBG11. The sample 
was subsequently purified, enabling a planar structure for each congener to be 
proposed based on MS/MS data and amino acid analysis. The structure for 
microviridin 1778A was further investigated by NMR spectroscopy but was 
not fully elucidated due to time constraints. 
 
The presence of the new aeruginosin and microviridin congeners indicated the 
diversity of the bioactive oligopeptides in the Microcystis strain. 
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Chapter 1:  Introduction 
 Cyanobacteria 
 
Cyanobacteria are ancient photosynthetic prokaryotes found in almost every 
conceivable environment on Earth. They comprise parts of many terrestrial and 
aquatic ecosystems and are some of the oldest known organisms on the planet, 
originating 3.5 billion years ago.1 Cyanobacteria are commonly known as blue-
green algae due to the bluish cell colour that results from a high concentration of 
phycocyanin2 and were apparently the first photosynthetic organisms capable of 
utilising water for the generation of cellular energy through photosynthesis.3 They 
contribute significantly to the nitrogen economy of terrestrial and aquatic habitats 
through their ability to fix atmospheric nitrogen into forms which can be utilised 
by other organisms.4  
 
There are five morphological orders of Cyanobacteria (Figure 1.1) which differ 
with respect to their size, shape and 16S ribosomal RNA sequences. Orders 
Nostocales and Stigonematales are monophyletic while orders Chroococcales, 
Oscillatoriales and Pleurocapsales are polyphyletic (being a taxonomic group 
that includes members, as genera or species, from different ancestral lineages).5 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1:  Microscopic view of the five morphological orders of Cyanobacteria. 
Adapted from Figure 2.1 of Reference 6. 
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Orders Chroococcales and Pleurocapsales are both unicellular but many strains of 
these orders can aggregate into irregular colonies. Both Chroococcales and 
Pleurocapsales have the ability to form baeocytes (internal spores) or endospores 
respectively. The remaining three cyanobacterial orders; Oscillatoriales, 
Nostocales and Stigonematales are multicellular and filamentous forms with 
trichomes (chains of cells). Order Oscillatoriales consists of uniseriated (arranged 
in one row) and unbranched trichomes with identical cells while orders 
Nostocales and Stigonematales consist of heterogeneous cellular trichomes with 
the presence of heterocytes (thick walled, transparent cells; capable of nitrogen 
fixation) and akinetes (large, thick walled cells which contain reserve materials 
for survival under unfavourable conditions).6 
 
Under favourable eutrophic conditions, cyanobacteria multiply to form planktonic 
blooms and dense benthic mats that hamper recreation by diminishing water 
clarity and producing bad odours and tastes. These blooms are sources of a variety 
of bioactive secondary metabolites including some compounds that are harmful to 
humans and animals (Table 1.1).3  
 
The cyanobacterial genera most commonly associated with the ability to produce 
toxic substances include; Anabaena, Aphanizomenon, Cylindrospermopsis, 
Lyngbya, Microcystis, Nodularia, Nostoc and Planktothrix.7 These secondary 
metabolites endanger other organisms including humans when consumed in 
drinking water or by physical contact during recreational activities. However, they 
are also a source of new pharmaceutical lead compounds due to their chemical 
diversity and biological activities.8 Cyanotoxins fall into various categories such 
as hepatotoxic, neurotoxic and those that cause dermal toxicity.1 Based on their 
structure, cyanotoxins can be divided into three groups: cyclic peptides, alkaloids 
and lipopolysaccharides.  
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Table 1.1:  Several classes of cyanotoxins and the cyanobacterial genera 
responsible for their production. 
 
 
 Cyanobacterial Peptides 
 
Cyanobacterial secondary metabolites display a vast diversity of structures. 
Among the known structures, the most commonly observed are linear or cyclised 
chains of amino acids called oligopeptides or cyanopeptides.9 These small 
compounds are mostly produced by freshwater planktonic cyanobacteria such as 
Anabaena, Microcystis and Planktothrix10 and are primarily produced by the non-
ribosomal peptide synthetase (NRPS) pathway, the polyketide synthetase (PKS) 
pathway or a hybrid of the two pathways.11 Cyanopeptides are grouped into 
classes with conserved structures which only differ by either exchange of an 
amino acid or modifications including methylation, glycosylation and 
halogenation.9 
 
More than 600 cyanobacterial peptides have been described from more than 30 
genera of all of the five morphological orders of cyanobacteria, however their  
 
Cyanotoxin 
Class 
Cyanotoxin Family Primary target 
(in mammals) 
Genera 
Cyclic 
peptide 
Microcystins Liver Microcystis, Anabaena, 
Oscillatoria (Planktothrix),a 
Nostoc, Hapalosiphon, 
Anabaenopsis 
Nodularin Liver Nodularia 
Alkaloid Anatoxin-a Nerve synapse Anabaena, Aphanizomenon, 
Oscillatoria (Planktothrix)a 
Anatoxin-a(S)b Nerve synapse Anabaena 
Aplysiatoxins Nerve synapse Lyngbya, Schizothrix,  
Oscillatoria (Planktothrix)a 
Cylindrospermopsins Liver Cylindrospermopsis, 
Aphanizomenon, 
Umezakia 
 Lyngbyatoxin-a Skin, gastro-intestinal 
tract  
Lyngbya 
 Saxitoxins Nerve axon Anabaena, Aphanizomenon, 
Lyngbya, 
Cylindrospermopsis 
Lipopolysaccharides  Potential irritants. 
Affect any exposed 
tissue 
All 
a Planktothrix was originally classified into the genus Oscillatoria, b Anatoxin-a(S) is an unique 
phosphate ester of a cyclic N-hydroxyguanine. Adapted from Table 3.1 of Reference 3. 
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function in the producing cells has not yet been unravelled.12  
 
Seven classes of cyanobacterial oligopeptides and their main bioactivities are 
reviewed in Table 1.2. They have attracted the attention of researchers over the 
past two decades based on the acute toxicity of some of these metabolites, their 
effect on human and animal health and the therapeutic use of several of these 
secondary metabolites.13  
 
Table 1.2:  The seven major oligopeptide classes and their main bioactivities. 
Oligopeptides Structure Bioactivity (Inhibitors) 
Anabaenopeptins Cyclic Protein phosphatase, carboxypeptidase-A  
Cyanopeptolins Cyclic Proteases  
Cyclamides Multicyclic Proteases 
Microcystins Cyclic with Addaa Protein phosphatases 1 and 2A  
Microginins Linear Proteases, angiotensin-converting enzyme 
Aeruginosins Linear Proteases  
Microviridins Cyclic Proteases, tyrosinase 
a 3-amino-9-methoxy-2,6,8-trimethyl-10-phenyl-4,6-decadienoic acid.  
Adapted from Reference 11.  
 
The focus of this research is the isolation and characterisation of cyanopeptides 
from a Microcystis species (CAWBG11) isolated from a cyanobacterial bloom  
sample obtained from Lake Hakanoa in 2005.14 These cyanopeptides include 
linear and cyclic peptides such as aeruginosin and microviridin which were 
detected during the course of Dr. Jonathan Puddick’s research in our group.15   
As a result of the previous investigation of these Microcystis samples, there were 
semi-purified samples with putative new congeners of aeruginosin and 
microviridin available, on which this research project is based. The main task in 
the current research is to structurally characterise some of the new congeners of 
aeruginosin and microviridin.  
 
1.2.1 Anabaenopeptins 
Anabaenopeptins are a group of cyclic hexapeptides which are characterised by 
the presence of D-lysine (Lys) in the second position and the formation of a ring 
through the carboxyl group of the position six amino acid and the primary ε-amine 
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of the Lys.9 The α-amine of Lys is linked to a side chain amino acid (position one) 
through an ureido bridge,16 such as in Anabaenopeptin MM913 (1).17 
 
 
 
 
 
 
 
 
 
 
 
(1) 
 
At least fifty two known variants of anabaenopeptins9,18 have been isolated and 
characterised from various cyanobacterial strains such as; Aphanizomenon flos-
aquae,19 Anabaena sp.,20 Microcystis aeruginosa,21 Oscillatoria agardii,22 
Nodularia spumigena,23 Lyngbya sp.18 Siliquariaspongia mirabilis,24 Schizothrix 
sp.25 and also from the marine sponge Theonella swinhoei.26 The genus Theonella 
has been shown to be one of the most prolific sources of bioactive natural 
products, some of which are almost certainly biosynthesised by symbiotic bacteria 
or cyanobacteria.26 All of the anabaenopeptins which have been characterised to a 
sufficient level contain D-Lys whilst the other amino acids are all in the L-
configuration and most of the variants tested are carboxypeptidase-A inhibitors.17 
 
1.2.2 Cyanopeptolins 
Cyanopeptolins are cyclic depsipeptides with the unusual structural element of  
3-amino-6-hydroxy-2-piperidone.9 The peptide ring is cyclised by an ester bond 
between the carboxyl group of the position six amino acid and the β-hydroxyl 
group of the position one threonine (Thr)27 such as in cyanopeptolin 1020 (2).28 
The side chain of the cyanopeptolins is attached via the amino group  
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of the position one Thr and consists of at least two amino acids and either an 
aliphatic fatty acid or a glyceric acid unit at the N-terminus. All of the amino acids 
of the cyanopeptolins presently described are in the  L-configuration.9 
 
 
 
 
 
 
 
 
(2) 
 
At least one hundred and twenty three known variants of cyanopeptolins9,29 have 
been characterised which were isolated from various cyanobacterial strains 
including; Aphanocapsa sp.,30 Planktothrix agardhii,31 Anabaena strain,32 
Microcystis sp.,33 Nosctoc sp.,34 Scytonema hofmanni,35 Chroococcales 
cyanophyceae36 and Symploca sp.37 
 
1.2.3 Cyclamides 
Cyclamides are a class of cytotoxic, cyclic hexapeptides with three azole or 
azoline rings, particularly thiazole and oxazole.9 They are characterised by a 
repeating motif of nitrogen and oxygen or sulphur containing, five-membered ring 
amino acids, with small, non-polar side chains,38 such as in  
aerucyclamide C (3).39 The formation of azole moieties is thought to be by 
dehydration and reduction of serine (Ser), Thr and cysteine (Cys) residues.9 
  
 
 
 
 
 
 
 
 
(3) 
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At least forty nine known variants of cyclamides9,40 have been isolated and 
characterised from various cyanobacteria including Microcystis sp.,40 Oscillatoria 
sp.,41 Lyngbya sp.,42 Stigonema dendroideum,43 Nostoc sp.,44 Westiellopsis 
prolifica45 and Lissoclinum bistratum which is a marine tunicate with a 
cyanobacterial symbiont.46 The cyclamides are divided into two subgroups; the 
first group are those that are derived from cyclisation of a hexapeptide containing 
two Cys and one Thr/Ser40 such as the tenuecyclamides,47 nostocyclamides44 and 
dendroamides.43 The second group are those derived from one Cys and two 
Thr/Ser moieties,40 including examples such as the raocyclamides,48 
microcyclamide49 and aerucyclamide.39 
 
1.2.4 Microcystins 
Microcystins (MCs) are cyclic peptides which are generally composed of the 
unique β-amino acid Adda (3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-
4,6-dienoic acid), D-glutamic acid (Glu), N-methyldehydroalanine (Mdha),  
D-alanine (Ala), D-erythro-β-methylaspartic acid and two variables 
L-amino acids,9 such as in (MC-FA) (4).14 Generally there are D-amino acids in 
positions one, three and six whilst positions two and four are occupied by variable 
L-amino acids and position seven is often occupied by Mdha.15 
 
 
 
 
 
 
 
 
 
(4) 
 
At least one hundred and twenty nine variants15 of microcystins have been 
characterised from many cyanobacterial genera including Anabaena,50  
Anabaenopsis,51 Aphanizomenon flos-aquae,52 Aphanocapsa,53 Arthrospira,54  
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Cylindrospermopsis,55 Fischerella,56 Hapalosiphon,57 Microcystis,58 Nostoc,59 
Oscillatoria,60 Phormidium,61 Planktothrix,62 Radiocystis,63 Synechocystis64 and 
Woronichinia.15  
 
1.2.5 Microginins 
Microginins are a class of linear lipopeptides that contain four to six amino acid 
residues. They are characterised by a decanoic acid derivative, 3-amino-2-
hydroxy-decanoic acid and a predominance of a tyrosine (Tyr) unit at the C-
terminus,65 such as in microginin GH78 (5).66  
 
 
 
 
 
 
 
 
(5) 
 
These compounds are of interest to many researchers because they are able to 
inhibit enzymes such as Leucine (Leu) amino peptidase M and the angiotensin-
converting enzyme (ACE). Inhibitors of ACE are the most effective treatments for 
hypertension and congestive heart failure or are target compounds in the 
discovery of novel antihypertensive agents.67 
 
To date, more than thirty variants of microginins 67 have been isolated and 
characterised from various cyanobacteria such as; Microcystis sp.,68 Nostoc sp.69 
and Oscillatoria agardhii.70 
 
1.2.6 Aeruginosins 
Aeruginosins are a group of linear modified tetrapeptides which are defined by 
hydroxyl-phenyl lactic acid (Hpla) at the N-terminus, varying hydrophobic amino  
acids in position two, 2-carboxy-6-hydroxyoctahydroindole (Choi) in the third  
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position and an arginine (Arg) derivative at the C-terminus,71 such as in 
aeruginosin 298A (6).72 
 
 
 
 
 
 
(6) 
 
The phenolic ring of Hpla is typically substituted with either hydroxyl groups or 
halogen substituents. Position two of the peptide is commonly occupied by a 
small, non-polar amino acid such as Leu or allo-isoleucine (Ile),71, 72 however Tyr 
and phenylalanine (Phe) have also been reported.73,21 The Choi moiety can be 
hydroxylated, sulphated or chlorinated at C6 (*) and the modified Arg C-terminus 
can be agmatine (Agma), arginol (Argol), argininal (Argal) and/or an amine.9  
 
The biological activities of aeruginosins are very dependent upon the 
modifications at Hpla, Choi and the C-terminus.38 Aeruginosins with an Argal or 
Agma at position four and a sulphate ester in Hpla or Choi are more potent 
protease inhibitors than those which contain an Argol or amine C-terminus.74  
 
1.2.6.1 Structural Diversity of Aeruginosins. 
More than thirty eight aeruginosin congeners (Appendix A.1) have been isolated 
from various cyanobacterial strains including Microcytis aeruginosa,71 
Microcystis viridis,73 Oscillatoria sp.,75 Nodularia spumigena76 and also from 
sponges such as Lamellodysidea chlorea77 and members of the Dysideidae 
family.78 The D-configuration is the most common for the amino acid in the 
second position, however exceptions have been observed in aeruginosins SF608, 
NAL2 and NOL6 where an L-amino acid was present.76, 79  
 
The majority of the known aeruginosins (60%) were reported from Microcystis  
aeruginosa and the remainder were from the other cyanobacterial strains stated  
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above. The following discussion of aeruginosin structural diversity is based on  
aeruginosins reported from the same cyanobacterial strain. 
  
The discovery of aeruginosin metabolites from Microcystis aeruginosa began in 
the early 1990s when Murakami and co-workers isolated aeruginosin 298A (6) 
from NIES-298 (Microbial Culture Collection, Japan) to consist of Hpla, Leu, 
Choi and Argol with the L-configuration for Leu71 which was later revised to the 
D-configuration.80 Aeruginosin 298A (6) actively inhibits the proteases thrombin 
(THB) and trypsin (TRP) at IC50 values of 0.3 μg/mL and 1 μg/mL respectively, 
but not other proteases such as papain (PAP), chymotrypsin (CTRP), elastase 
(ELT) and plasmin (PLM).81   
 
In the following year, the same group isolated aeruginosins 98A (7) and 98B (8) 
which contained a meta-halogenated-Hpla, Ile, sulphated Choi and Agma.82 
Similar variants were also isolated in 1999 by Ishida and co-workers as 98C (9) 
and 101 (10), together with others such as 298B (11), 89A (12) and 89B (13).  
 
 
 
 
 
 
 
 
(7) R1 = Cl, R2 = H 
(8) R1 =  R2 = H 
(9)  R1 = Br, R2 = H 
(10)  R1 = R2 = Cl 
 
The structure of aeruginosin 298B (11) resulted from lack of the Argol moiety 
which is present in aeruginosin 298A (6). The amino acid in position two was 
originally assigned as L-Leu 83 but was later revised to the D-configuration.80 
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     (11) 
 
Aeruginosins 89A (12) and 89B (13) are stereoisomers which contain chloro-
sulphated Hpla, Leu and Choi and different conformations of Argal at the           
C-terminus. 
 
 
 
 
 
 
(12) (2S) 
(13) (1S,2R) 
 
Another variant, known as SF608 (14), was isolated by Carmeli and Banker with 
a composition of L-Hpla, L-Phe, L-Choi and Agma. The presence of the L-Phe 
residue is an exception to the usually observed D-amino acid in position two.79 
 
 
 
 
 
 
(14) 
 
In 2001, a second aeruginosin lacking the usual guanidine-containing C-terminus, 
aeruginosin EI461 (15) was isolated from a Microcystis aeruginosa strain  
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collected from Einan Reservoir in Israel by Carmeli et al.84 The structure was very 
similar to aeruginosin 289B (11) but with different stereochemistry at the Choi 
moiety. Aeruginosin EI461 (15) was determined to be the only member of the 
aeruginosins with an anti-relationship between H-2 and H-3a/H-7a of the Choi 
moiety.84 
 
 
 
 
 
(15) 
 
Raveh and Carmeli isolated two more aeruginosins; KY642 (16) and KY608 (17) 
in 2008 from a cyanobacterial bloom collected at a water reservoir near  
Kfar-Yehoshua, Valley of Armageddon, Israel. These variants were very similar 
to aeruginosin 101(10) but with an hydroxyl-C6 instead of a sulphate on the Choi 
moiety.85 
 
In 2012, Carmeli and co-workers isolated five similar halogenated aeruginosins 
from a bloom collected at Kibbutz Geva, Israel and designated the new 
constituents as aeruginosins GE686 (18), GE730 (19), GE766 (20), GE810 (21) 
and GE642 (22).72  
 
 
 
 
 
 
(16) R1= R2 = Cl, R3 = OH 
(17) R1= Cl, R2 = H, R3 = OH 
(18) R1= Cl, R2 = Br, R3 = OH 
(19) R1= R2 = Br, R3 = OH 
(20) R1= Cl, R2 = Br, R3 = OSO3H 
(21) R1= R2 = Br, R3 = OSO3H 
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Aeruginosin GE 642 (22) differs from the other metabolites isolated from the 
Kibbuts Geva bloom material by the inclusion of Leu at position two instead of Ile. 
 
 
 
 
 
 
 
(22) R1 = R2 = Cl 
 
In the same year, Lifshits and Carmeli isolated another five aeruginosins;  
KT608A (23), KT608B (24), KT650 (25), KT554 (26) and GH553 (27) from a 
bloom collected at Lake Kinneret, Israel.21  
 
Aeruginosins KT608A (23) and KT608B (24) were composed of D-Phe, D-Choi 
and Agma but contained L- and D-stereoisomers of the Hpla moiety respectively. 
Aeruginosin KT 650 (25) differed by acetylation of the Hpla C2-OH. 
 
 
 
 
 
 
(23) R1 = OH (L-Hpla) 
(24) R1 = OH (D-Hpla) 
(25) R1 = OOCCH3 (D-Hpla) 
 
Aeruginosin KT 554 (26), a pseudoaeruginosin, contains Phe in position three  
instead of Choi and aeruginosin GH553 (27) is very similar to 298B (11) except 
that the usual guanidine-containing C-terminus is replaced with an acetylated 
Choi and a Tyr at the second position.21 
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(26) 
 
 
 
 
 
 
 
 
(27) 
 
The most recent report of aeruginosins from Microcystis aeruginosa was in early  
February 2013 by Carmeli and co-workers who isolated aeruginosin IN608 (28) 
and IN652 (29). The cyanobacterial strain was isolated from a bloom collected at 
Durgakund water reservoir in Varanasi, India and both aeruginosins are very 
similar to aeruginosin GE642 (22) and only differ by halogenation at the Hpla 
moiety. Both compounds are inhibitors of the proteolytic enzyme TRP.86  
 
 
 
 
 
 
 
(28) R1 = Cl,  R2 = H 
(29) R1 = Br,  R2 = H 
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To date, only three aeruginosins have been isolated from Microcystis viridis. In 
1996, Matusda et al. reported the isolation of aeruginosins 102A (30) and 102B 
(31) which contained a sulphated Hpla, Tyr, Choi and Argal. These two 
compounds were isomers with differing stereochemistry of the C-terminus.73 
 
 
 
 
 
 
                                                                                          * 
 
(30) L-Argal (3S*) 
(31) D-Argal (3R*) 
 
In 1998, Murakami and co-workers isolated and characterised aeruginosin 103A 
(32) which had a structure similar to that of 102A (30) but with an unique  
1-amidino-2-ethoxy-3-aminopiperidine (Aeap) subunit which contains a cyclic 
ethyl hemiaminal.87 
 
 
 
 
 
 
 
     (32) 
 
There have been several aeruginosins isolated from Oscillatoria agardhii. The 
first, aeruginosins 205A (33) and 205B (34) were isolated in 1997 from 
Kasumiguara Lake, (Japan) by Shin and co-workers and contained an unusual 
linear glucopeptide. They comprised phenyllactic acid-2-O-sulphate (Plas) in 
position one, 3-hydroxyleucine (HLeu) and xylopyranose (Xyl) in position two 
respectively, 2-carboxy-6-chlorooctahydroindole (Ccoi) in position three and  
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Agma at the C-terminus. The presence of HLeu is very rare in naturally occurring 
metabolites88 and both aeruginosins were found to have opposite stereochemistry 
at the Plas and HLeu.75 
 
 
 
 
 
 
 
(33) L-Plas, 2R,3S,2'S (Hleu)  R =   
(34) D-Plas, 2S,3R,2'R (Hleu) 
 
In the same year, Konetschny-Rapp and co-workers isolated and characterised 
oscillarin from Oscillatoria agardhii collected from Lake Kasumiguara (Japan).  
The metabolite was initially determined to comprise of D-Plas, D-Phe, L-Choi and 
a cyclic guanidine (35)89 but later revised to consist of a 1-(N-amidino-Δ3-
pyrrolino)ethyl subunit (Adc) (36) at the C-terminus.90 
 
 
 
 
 
 
 
 
(35) R =     (36) R =  
       
 
 
In September 2013, two new aeruginosins were reported from the filamentous, 
diazotrophic Nodularia spumigena by Fewer et al. These aeruginosins; NAL2 (37) 
and NOL6 (38) were Ser protease inhibitors and comprised a rare N-terminal 
short fatty acid chain. In addition NOL6 (38) also containing a rare pentose sugar 
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modification on the Choi. These were the first aeruginosins reported with a short 
fatty acid chain at the N-terminus instead of Hpla or Plas.76 Additionally, these  
metabolites contained a position two amino acid in the L-configuration as with 
SF608 (14).76  
 
 
 
 
 
 
 
(37) 
 
 
 
 
 
 
 
 
 
(38) 
 
Other interesting aeruginosin structures have been identified, including the first 
aeruginosin to contain both a fatty acid and a carbohydrate at the Choi moiety; 
Aer856 (39). This was also the first aeruginosin to be found in the genus Nostoc 
and the sample was obtained by Kapuścik and co-workers (2013) from the forest 
soil of the Kruŝné mountains, Czech Republic. The peptidic sequence of Aer856 
(39) was D-Hpla, D-Leu, 5-OH-Choi, Agma, with hexanoic and mannopyranosyl 
uronic acid moieties linked to Choi. The compound displays remarkable anti-
inflammatory activity with no cytotoxic or barrier disruption effects, which makes 
it an interesting immunomodulatory agent.91  
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(39) 
There have been a several aeruginosin-like metabolites isolated from marine 
sponges such as Lamellodysidea chlorea and members of the family Dysideidae 
found in North Queensland, Australia.77,78 These bioactive metabolites were 
believed to be produced by symbiotic cyanobacteria.92  
 
In 2002, Quinn and co-workers isolated dysinosin A (40) as a potent inhibitor of 
the blood coagulation cascade factor VIIa2 and a peptidic THB inhibitor with 
significant structural similarities to the aeruginosins. It was composed of an Adc 
subunit as in oscillarin (37), but with an additional hydroxyl group at C5 of the 
Choi moiety and the N-terminal residues were D-Leu and a sulphated glyceric acid 
derivative which has not been reported in known aeruginosins.78 
 
In 2003, a similar metabolite was isolated; chlorodysinosin A (41) which 
contained 2S,3R-3-chloroleucine. It was a potent inhibitor of the Ser proteases; 
THB, factor VIIa and factor Xa, which are critical enzymes in the process leading 
to platelet aggregation and fibrin mesh formation in humans.93 
 
 
 
 
 
 
(40) R = H 
(41) R = Cl 
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In 2004, three similar metabolites were isolated from the sponge Lamellodysidea 
chlorea by the same group, which were designated as dysinosin B-D (42-44) and 
are inhibitors of THB and the blood coagulation cascade Ser proteases factor 
VIIa.77 
 
 
 
 
 
 
(42)  R1
 = SO3
-, R2 = A  A = 
(43)  R1
 = H,  R2 = SO3
-   
(44)  R1
 = H,  R2 = H 
 
The isolation and structural characterisation of the aeruginosin variants above 
were determined using common methods such as octadecylsilyl flash 
chromatography, reversed-phase (RP) high performance liquid chromatography 
(HPLC), liquid chromatography-mass spectroscopy (LC-MS), high resolution 
fast-atom bombardment mass spectrometry (HRFABMS), high resolution x-ray, 
1D and 2D nuclear magnetic resonance (NMR) spectroscopy, amino acid 
degradation and derivatisation.94  
 
1.2.6.2 Inhibitory Activities of Aeruginosins. 
The members of the aeruginosin family are potent inhibitors of the Ser proteases 
TRP, THB and PLM (Table 1.3). Ser proteases are involved in a number of vital 
physiological processes and are important in the complex blood coagulation 
cascade.76 The modification of the C-terminus plays a significant role for the 
bioactivities of the aeruginosins. Aeruginosins which lack a guanidine-containing 
C-terminus such as aeruginosins 298B (11), EI461 (16) and GH553 (27) show no  
Ser protease inhibition. Metabolites which contain Argal are stronger protease 
inhibitors compared to those which contain Agma and Argol.87 They are more 
potent against THB and thus the aldehyde of Argal is very important to inhibit 
THB.95 The bulky Argal ethyl aminal structure of the Aeap unit in 103A (32) 
reduced the TRP inhibitory activity.87  
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Table 1.3:  Inhibitory activities of aeruginosins against thrombin, trypsin, plasmin 
and FVIIa. 
 
Aeruginosin Bioactivities (IC50 µg/mL) 
Thrombin Trypsin Plasmin FVIIa 
298A (6) 0.3 1 >10 - 
98A (7) 7 0.6 6 - 
98B (8) 10 0.6 7 - 
98C (9) 3.2 3 3.3 - 
101 (10) 3.3 3.9 5 - 
298B (11) >100 >100 >100 - 
89A (12) 0.03 0.4 0.02 - 
89B (13) 0.05 6.6 0.46 - 
SF608 (14) - 0.5 - - 
EI461(15) - 15%  - - 
KY642 (16) - 1.4 - - 
KY608 (17) - 1.7 - - 
GE686 (18) 12.8 3.2 - - 
GE730 (19) 12.9 2.3 - - 
GE766 (20) >45.5 18.2 - - 
GE810 (21) >45.5 12.2 - - 
GE642 (22) >45.5 18.2 - - 
KT608A (23) 30%a 1.9 - - 
KT608B (24) <50% 1.3 - - 
KT650 (25) <50%  19.9 - - 
KT554 (26) - 45.5 - - 
GH553 (27) - 45.5 - - 
IN608 (28) - 4.3 - - 
IN652 (29) - 4.1 - - 
102A (30) 0.04 0.2 0.3 - 
102B (31) 0.1 1.1 0.8 - 
103A (32) 9 51 68 - 
205A (33) 1.5 0.07 - - 
205B (34) 0.07 0.07 - - 
Oscillarin (35) 0.018 0.024 >260 2.5 
NAL2 (37) ndb nd nd - 
NOL6 (38) nd nd nd - 
Aer856 (39) - - - - 
DysA (40) 0.29 - - 0.21 
Cl-DysA (41) 0.004 0.025 - 0.02 
DysB (42) 0.13 - - 0.07 
DysC (43) 0.34 - - 0.07 
DysD (44) >3.3   0.86 
a inhibit at concentration of 45.5µg/L, b not detected.  
Similar to Table 1 of Reference 88. 
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The compounds with 6-OH Choi are more potent toward TRP and THB compared 
to those containing a 6-sulphated Choi such as aeruginosin GE686, GE730 and 
GE 642 (18-20).72 However, the halogen substituent of the Hpla moiety does not 
influence the potency of the aeruginosins such as GE686 (18), GE730 (19), IN688 
(29) and  IN652 (30).86 The aeruginosins from sponges which contained an 
octahydroindole system and lacked a sulphated group such as dysinosin D (44) 
were less potent against FVIIa and THB.77 
 
1.2.6.3 Biosynthesis of Aeruginosins. 
In 2009, Ishida et al. provided the first insight into the molecular basis of the 
biosynthetic pathway of aeruginosin by analysing and comparing the aeruginosin 
synthetase (aer) gene clusters from Microcystis sp. and Planktothrix agardhii.96 It 
was indicated that the biosynthesis of aeruginosin was very much dependent on 
the specific NRPS and PKS genes, yet only a few studies have been carried out to 
date.96 
 
The aer gene cluster had sequences from strains of Planktothrix agardhii 
CYA126/897 and Microcystis strains PCC 7806,98 NIES-84399 and NIES-98.96 The 
entire gene cluster (aerA-N) totals a size of 25-27 kb and was similarly organised 
between different cyanobacterial strains. The first three NRPS modules encoding 
aerA, aerB and aerG were coding for hybrid NRPS/PKS enzyme complex. The 
regions coding for tailoring enzymes such as halogenases and sulphotransferases 
depend upon the individual cyanobacterial strains.96  
 
In Planktothrix agardhii CYA126/8, the biosynthesis started with the activation of 
an aryl acid; phenylpyruvate, the keto group of which was reduced by the 
ketoreductase domain of the first module (aerA). Similarly, in Microcystis strains, 
the biosynthesis was assumed to start with an hydroxy-phenylpyruvate which was 
reduced to Hpla (Figure 1.2).96 
 
The putative Falvin adenine dinucleotide (FADH2)-dependent halogenase gene 
aerJ, was responsible for the formation of the non-, mono- and di-halogenated 
variants of the Hpla moieties of Microcystis strains12 and also at the Choi moiety 
from Oscillatoria agardhii.75 The presence or absence of this halogenase gene  
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was one of the reasons for the structural diversity observed in aeruginosins. 
Although only a few studies have been carried out, the halogenated aeruginosins 
are known to be isolated from Microcystis species, thus it was assumed that aerJ 
was a characteristic of the Microcystis strain.12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2:  Schematic representing the biosynthetic pathways for the production 
of aeruginosins 98A (7), 98B (8) and 101 (10) in Microcystis strain 
NIES-98. Adapted from Reference 96. 
 
The condensation, thiolation and epimerisation domains present in aerB, 
incorporated the amino acid at the second position into the structure. Invariably 
the conformation of this epimerisation domain was consistent with the 
 D-configuration of the position two amino acids incorporated in most 
aeruginosins.97 
 
The genes responsible for Choi formation in Microcystis were aerD-F and aerK  
 23 
 
whereas in Planktothrix, these genes are located in aerC. 97 Different pathways of 
Choi formation were assumed to operate in each strain. The presence of aerK was 
essential for the synthesis of aeruginosin only in Microcystis yet the precursor for 
Choi has not been defined.96 Ishida et al. (2007) proposed that biosynthesis of 
Choi in a Planktothrix strain involved oxidation of arogenate (pretyrosine) by 
aerC, followed by cyclisation via Michael addition in aerE to produce vinylogous  
β-keto acid which was then decarboxylated by aerD to yield a bicyclic amino acid  
which may be reduced by aerF to the Choi moiety.97 
 
The sulphotransferase AerL was responsible for the sulphonation of the 
aeruginosins produced by M. aeruginosa NIES-98 and NIES-843. The 
sulphonation at Hpla and Choi were different in each strain. The Choi 
sulphonation was likely to be accomplished after the formation of the Choi-
phosphopanthetheine thioester.12 
 
At the incorporation of the last moiety into the aeruginosin molecules, the Agma 
was bound to the peptidyl carrier protein (PCP)-bound carboxyl group of Choi 
and release of the peptide was triggered by amide bond formation between the 
PCP-bound carboxyl group for Choi and the primary amine of Agma.97 
 
The glycosyl transferase genes present in the aer gene cluster in Planktothrix 
agardhii were absent from the gene cluster found in the Microcystis strain, hence 
the aeruginosins produced were not glycosylated. However glucosylation of 
aeruginosin had been observed exclusively and frequently in Planktothrix strains, 
indicating a possible genus-specific association of this gene with the aer gene 
cluster.96 
 
1.2.7 Microviridins 
Microviridins are tricyclic depsipeptides comprising thirteen or fourteen amino 
acids, seven of which are conserved; Thr [4], Lys [6], Tyr [7], Proline (Pro) [8], 
Ser [9], Aspartic acid (Asp) [10] and Glu [12],9 as observed in microviridin A 
(45).100 They are the largest known cyanobacterial oligopeptides9 and are one of 
the most intriguing classes of peptides, with a cage-like structure and highly 
unusual tricyclic architecture with ω-ester and ω-amide bonds between the  
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alcoholic, acidic and amine side chains of several of the conserved residues.100  
 
 
 
 
 
 
 
 
 
 
 
 (45) 
 
The main peptide ring consists of seven amino acids with a peptide (amide) bond 
between the 6-amino group of Lys [6] and the sidechain carboxy group of Glu, 
Asp or homoaspartic acid (Has) [13]. Di-cyclisation of the structure occurs 
through an ester bond between the 4-carboxyl group of Asp [10] and the hydroxyl 
group of Thr [4]. The final ring is formed through another ester bond between the 
side chains of Ser [9] and Glu [12].9 These bonds are indicated by circles on 
microviridin A (45) above. The ester linkages can undergo partial methylation or 
methanolysis which contributes to several of the reported structures for 
microviridins.101 
 
1.2.7.1 Structural Diversity of Microviridins. 
To date, fifteen microviridin congeners (Appendix A.2) have been isolated from 
various cyanobacterial genera such as Microcystis, Oscillatoria and Nostoc.100-105 
The structural diversity of microviridins was due to variation of the amino acids 
incorporated at the non-conserved positions together with the presence or absence 
of the two ester linkages between the amino acids at positions four/ten and 
positions nine/twelve. The amide bond formed between Lys and the amino acid in 
position thirteen is conserved in all of the known structures of the metabolites. To 
date, all of the amino acids incorporated into microviridins have been in the        
L-conformation.9 
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The majority of the isolated microviridins (seven) were obtained from Microcystis 
aeruginosa.100-103 Only one microviridin has been reported from Microcystis 
viridis,104 five congeners have been isolated from Oscillatoria agardhii105-107 and 
two have been reported from Nostoc minutum.108  
 
Microviridin A (45) was isolated from a Microcystis viridis strain obtained from 
Kasumigaura Lake, Japan in 1990 by Ishituska and co-workers. It was the first 
tricyclic depsipeptide with fourteen amino acids to be reported from natural 
sources and strongly inhibited the Ser protease, tyrosinase.104 
 
Five years later, microviridins from Microcystis aeruginosa were initially reported 
by Okino et al. as microviridin B (46) and C (47).  
 
 
 
 
 
 
 
 
 
 
(46) A = √, B = x 
(47)  A = √, B = √ 
x = ester linkage absent, √ = ester linkage present 
 
These two microviridins also comprised fourteen amino acids but as tricylic and 
bicyclic depsipeptides respectively. Microviridin C (47) had no ester linkage 
between Ser in position ten and Glu in position twelve. They were potent 
inhibitors of ELT with potential for use as therapeutic agents of pulmonary 
emphysema.102 
 
Microviridin J (48) was isolated in 2003 by Rohrlack et al. from a bloom 
collected at Malpas Dam, Australia. It was a tricyclic depsipeptide with thirteen  
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amino acids and was an inhibitor of porcine TRP, bovine CTRP and daphid TRP-
like protease. It also caused lethal molting disruption in Daphnia spp., upon 
ingestion of living cyanobacterial cells.101 
 
 
 
 
 
 
 
 
 
 
 
(48) 
 
In 2006, Reshef and Carmeli isolated microviridins SD1684 (49), SD1634 (50) 
and SD1652 (51) from a bloom collected in 1998 from a pond in the Dan District 
sewage treatment plant, Shofdan, Israel. These microviridins were the first to 
contain a non-proteinogenic amino acid in their structure; L-threo-β-hydroxy Asp 
in position thirteen. They each have thirteen amino acids in the 
 L-configuration and are differentiated by the two ester linkages; SD1684 (49) 
contains no ester linkages, making it a monocyclic peptide, SD1634 (50) is 
tricyclic and SD1652 (51) is a bicyclic peptide. All three microviridins were mild 
Ser protease inhibitors.103 
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(49) A = x, B = x 
(50) A= √, B = x 
(51) A= x, B = √  
x = ester linkage absent, √ = ester linkage present 
 
In 2010, microviridin L (52) was isolated from a bloom of Microcystis aeruginosa 
from Lake Kasumigaura, (Japan) by Zeimert and coworkers. It was a tricyclic 
peptide with fourteen amino acids which inhibited TRP. 100   
 
 
 
 
 
 
 
 
 
 
 
 
(52) 
 
Microviridin variants were isolated from Oscillatoria agardhii, including 
microviridins D-F (53) - (55) discovered by Shin et al. (1996) from a bloom 
obtained from the NIES-collection, (Microbial Culture Collection, National 
Institute for Environmental Studies, Japan). Microviridin D (53) was a bicyclic 
depsipeptide with fourteen amino acids which differs from E (54) and F (55) by 
the amino acids in the first three positions and at position five and eleven. All are 
potent inhibitors of Ser protease and D (53) and E (54) also inhibited CTRP while 
F (55) did not at 100 µg/mL.105 
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     (53) 
 
 
 
 
 
 
 
 
 
 
 
(54) A= x, B = √  
(55) A=√, B = √ 
x = ester linkage absent, √ = ester linkage present 
 
In 2001, Fujii et al. reported the isolation of microviridin I (56) from non-toxic 
Oscillatoria agardhii strains; 97 (Lake Maarianallas, Findland) and CYA 128 
(Lake Vesijärvi, Findland). It was a depsipeptide with fourteen amino acids which 
inhibits ELT with an IC50 value of 0.34 µg/mL.
107 
 
 
 
 29 
 
N
H
N
H
O
O
O
NH
O
NH
NH
OH
O
NH
O
O
N
O
O
O
N
H
NH
OH
O
O
NH
N
H
O
O
NH
OH O
N
O
N
H
O
OH
N
H
OH
O
O
OH
NH
MeO
N
H
N
HO
OH
O
N
H
N
H
O
O
O
NH
O
NH
NH
OH
O
NH
O
O
N
O
O
O
N
H
NH
O
O
NH
NH
N
H
O
O
N
H
OH
O
OH
O
NH
NH2O
S
O
O
 
 
 
 
 
 
 
 
 
 
 
(56) 
 
Microviridin K (57) was discovered in 2009 from Oscillatoria (Planktothirix) 
agarhdii NICA-CYA 126/8 by Philmus and co-workers. Its amino acid 
composition was very similar to that of microviridin D (53) with both ester 
linkages being present. It was presumed that microviridin K (57) is a methanolysis 
product, so biological activities of this metabolite were not determined.106, 109  
 
 
 
 
 
 
 
 
 
 
(57) 
The only microviridins isolated from Nostoc minitum, microviridins G (58) and H 
(59) were reported by Murakami and co-workers in 1997. They both comprised 
the same fourteen amino acids but microviridin H (59) lacked the ester linkages 
between the position nine Ser and the position twelve Glu. Both metabolites were 
found to be potent inhibitors of ELT.108 
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(58)  A= √, B = √ 
(59)  A= √, B = x 
x = ester linkage absent, √ = ester linkage present 
 
Some microviridin congeners lack an ester linkage or contain a methyl ester. At 
times, these latter congeners have been shown to be a result of the isolation and 
purification processes when using methanol as a solvent.110 Rohrlack et al. 
indicated that incubation of metabolites with methanol at high temperature 
resulted in methylation of one of the ester linkages.101 To avoid these processes, 
the sample should be kept at 5 ºC and either 50% methanol (MeOH)101 or a more 
hindered alcohol solvent such as isopropanol should be used for extraction and a 
lipophilic solvent such as acetonitrile (ACN) should be used for RP 
chromatography. However this does not disprove the potential for these variants 
to occur naturally.110 
 
The isolation and structural characterisation of the above microviridins were 
determined with common spectroscopic and chemical analyses such as HPLC, gel 
column filtration chromatography, RP FABMS, NMR spectroscopy, gas 
chromatography mass spectrometry (GC MS) and amino acid analysis.  
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1.2.7.2 Inhibitory Activities of Microviridins. 
The amino acid composition of the metabolite is very important for the biological 
activities of the microviridins (Table 1.4). The significance of the amino acid at 
the fifth position, between Thr and Lys was highlighted when comparing the 
structures of the known microviridins and their biological activities.  
 
Microviridins with Leu in position five (microviridins B (46), C (47), F (55),  
I (56), G (58) and H(59)) are potent inhibitors of ELT, while the presence of 
Methionine (Met), Tyr or Phe in the same position resulted in weak (microviridins 
D (53), E (54), F (55) or no inhibitory effects on ELT (microviridin A (45)).107, 108 
In addition, absence of a hydrophilic amino acid residue in position three 
(microviridins A (45), SD1684 (49), SD1634 (50), SD1652 (51) and K (57)) 
resulted in no ELT inhibition. The ester linkage with the hydroxyl group of Ser 
was shown to not be important for ELT inhibition (microviridin A (45)).108 
 
Table 1.4:  Inhibitory activities of isolated microviridins against elatase 
chymotrypsin and trypsin. 
Microviridin Inhibitory Activity ( IC50 µM) 
 Elastase  Chymotrypsin  Trypsin  
A (45) >58a >58 >58 
B (46) 0.026 1.5 34 
C (47) 0.048 2.8 18 
J (48) >6 1.7 20-90 
SD1684 (49) ndb inactivec inactive 
SD1634 (50) nd 15.7 8.2 
SD1652 (51) nd inactive inactive 
L(52) nd nd nd 
D (53) 0.388              0.7 >55 
E (54) 0.360 0.7 >60 
F (55) 0.034 >59 >59 
I (56) 0.193 nd nd 
K (57) >58 42 5.8 
G (58) 0.010 0.78 >55 
H (59) 0.017 1.6 >54 
a no inhibitory activity has been detected below this value, b not 
determined,cinactive at 45µM. Adapted from Table 3 of Reference 100. 
 
Microviridin J (48) has an Arg in position five which may account for the strong 
TRP inhibitory action while at the same time negating its inhibitory effect on  
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ELT.101 A similar effect may occur in microviridins SD1684 (49), SD1632 (50) 
and SD1652 (51) with the Arg residue. As only SD1632 (50) displays TRP 
inhibition, and since microviridins SD1684 (49) and SD1652 (51) have no ester 
bond between the Asp [10] and Thr [4], this indicates that this ester linkage is 
important for TRP-inhibition.103 
 
In addition to the main acid at the fifth position, a hydrophilic residue at the 
position just before Thr and the ester linkage between Thr and Asp appear to be 
crucial for inhibitory effects on ELT.108 
 
1.2.7.3 Biosynthesis of Microviridins. 
The genetic basis of microviridin production was initially assumed to be by a 
NRPS pathway as with the cyanopeptolins.111 However, two groups which 
independently studied microviridin biosynthesis using different approaches 
detected that microviridins were produced via a ribosomal assembly route with 
subsequent tailoring functions to produce the final structure.106, 112 Zeimert and 
co-workers pursued a strategy of heterologous expression of the microviridin 
cluster from Microcystis aeruginosa NIES 298112 in E. coli while Philmus and co-
workers pursued in vitro reconstitution of parts of the pathways from Planktothrix 
agardhii CYA 126/8.112 
 
The gene cluster for the biosynthesis of microviridin B from Microcystis 
aeruginosa NIES298 (mdn) was about 6 kb and contained five genes (mdnA-E). It 
consisted of two genes encoding adenosine triphosphate (ATP)-grasp type ligases 
(mdnB and mdnC), a gene coding for a putative peptide precursor (mdnA), a gene 
for an ATP-binding cassette (ABC) transporter (mdnE) and an N-acetyltransferase 
of the Gcn5-related N-acetyltransferase (GNAT) family (mdnD).112 The steps 
involved in the biosynthesis of microviridin B are shown in Figure 1.3.   
 
The mdnA gene consisted of a leader peptide and a core peptide which encoded 
the precursor molecule for microviridin production.112 The presence of N-terminal 
leader peptides is a common feature for ribosomal peptides, which is very 
important for their processing and cellular export by a transporter peptidase.112,113 
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Figure 1.3:  Schematic representating the biosynthesis of microviridin B (45) in 
Microcystis aeruginosa NIES298. (Letters represent amino acids 
using the common code). Adapted from Reference 110.        
 
Weiz et al. (2011) investigated the role of the leader peptide in the biosynthesis of 
microviridin and deduced that there was a strictly conserved motif “PFFARFL” in 
all of the leader peptides of the identified gene clusters for microviridin 
(highlighted in the leader peptide of Figure 1.3). This conserved motif served as a 
recognition motif for the ATP-grasp gene which was essential for the post-
translational modification of microviridin.106, 113 The presence of the Arg residue 
in the motif was crucial for the activity of the ATP-grasp like enzyme introducing 
the lactam function or cyclic amide.112 
 
The MdnB and MdnC ligases belong to a family of enzymes with ATP-grasp fold. 
These enzymes were used to form the peptide bond by conducting an ATP-
dependent carboxylate-amine thioligase activity upon primary and secondary 
amines.114 The MdnB and MdnC ligases catalysed the ring closure in microviridin 
biosynthesis, for example, the MdnC introduced the two rings, starting with the 
larger one. The activity of MdnB relied on MdnC activity and can establish the 
peptide bond only once the ester bond formations were completed. MdnB and  
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MdnC cyclised the ring with leader peptide intact prior to its cleavage.112 MdnD 
then acetylates the completely processed microviridins at the N-terminus.106 The 
ABC-transporter encoded by mdnE was assumed to be involved in proteolytic 
cleavages and translocation of microviridin B.112 It strongly influences the 
stability of the putative biosynthetic complex, which could be due to the 
membrane and ATP-binding domains anchoring the putative microviridin 
complex.113 
 
Philmus and co-workers suggested an orthologous gene cluster for the 
biosynthesis of microviridin K in Planktothrix agardhii CYA126/8. The 
biosynthetic gene cluster encoded as mvdA-F was designated as two structural 
genes of microviridin prepeptides (mvdE and mvdF), two genes for grasp-like 
ligases (mvdC and mvdD), one gene for an acetyl transferase (mvdB) and an ABC 
transporter (mvdA).106, 113 Three of the four post-translational modifications 
required to convert linear peptide mvdE into microviridin K are indicated in 
Figure 1.4.106 
 
The prepeptide of microviridin K was encoded by mvdE which required 
proteolytic processing as part of the post-translational modification process. It is 
composed of a leader peptide and a core peptide (YGNTMKYPSDWEEY). The 
gene mvdF appeared to encode another putative microviridin, however this 
microviridin was not detected in extracts of P. agardhii.106  
 
MvdD catalysed the two ester linkages by formation of a carboxylated-phosphate 
mixed anhydride with release of adenosine diphosphate (ADP), followed by the 
release of phosphate upon esterification.106 The macrocyclisation of the peptide 
depends upon the two ATP-grasp-type ligases; MvdD and MvdC.110 The amide 
bond is formed by MvdC after the two ester linkages have been formed. The 
cleavage of the leader peptide requires a protease which is not present in the mvd 
gene cluster and the terminal acetylation is achieved by the acetyltransferase 
MvdB.106 
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Figure 1.4:  Schematic of the biosynthetic steps for production of microviridin K 
(57) in Planktothrix agardhii CYA126/8 (Letters represent amino 
acids using the common code). Adapted from Reference 108. 
 
The structural modifications of the microviridin introduced during the maturation 
were the formation of the two ester bonds and one amide bond. Further maturation 
of the peptide was achieved by cleavage of the leader peptide and N-terminal 
acetylation.110 The different approaches of the two research groups have labelled 
the biosynthetic gene clusters differently but with a common indication of the 
presence of a ribosomally-produced precursor peptide, grasp-like ligases, an ABC 
transporter and an N-acetyltransferase.100  
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2 Chapter 2:  Aeruginosin Metabolites from Microcystis CAWBG11. 
 Introduction 
Aeruginosins are a group of structurally diverse bioactive oligopeptides produced 
by bloom-forming cyanobacteria of the genera Microcystis, Planktothrix, 
Nodularia and Nostoc. In addition, they are also produced by symbiotic 
cyanobacteria of marine sponges Lamellodysidea chlorea and by members of the 
Dysideidae family.13-18,78,91  Aeruginosins are tetrapeptides containing the  
N-terminal Hpla, an unusual Choi moiety at position three, a C-terminal Arg 
derivative and a variable hydrophobic amino acid in position two (see 
Section 1.2.6).9 
 
The metabolites are inhibitors of the Ser proteases; TRP, THB and PLM.88 Thirty 
eight aeruginosin variants have been isolated and characterised since the 1990s, 
however, additional cyanopeptides belonging to the aeruginosin family such as 
aeruginosins 586, 602, 670 and 678 are not included in the known lists as they 
have not been fully characterised or biologically tested against Ser  
proteases.11, 115, 116 
 
In the current chapter, Microcystis CAWBG11 was screened for known and new 
aeruginosins. Four known aeruginosins 298A (6), 298B (11), EI461 (15) and 
602A (60)95, 115, 117 were detected in a methanol extract of Microcystis CAWBG11, 
as well as four new aeruginosins which were characterised by tandem mass 
spectrometry (MS/MS) and Advanced Marfey’s amino acid analysis. In addition, 
the known aeruginosin 602A (60)115 was characterised by NMR spectroscopy to 
confirmed the putative structure proposed by Welker et al. 115. 
  
 Characterisation of aeruginosin-like compounds from Microcystis 
CAWBG11. 
The LC-MS analysis of a methanol extract of Microcystis CAWBG11 indicated 
the presence of various ions at m/z 462, 603, 605, 619 and 657 ( Figure 2.1; Table 
2.1) which were within the mass region of the aeruginosins. Initially 
discrimination of known from new aeruginosin congeners was achieved by 
comparison of molecular masses of the detected ions with those of known  
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aeruginosins. The confirmation of the known aeruginosins with molecular mass 
461Da (A and B), 602ADa (A) and 604 Da was done by MS/MS data analysis. 
The aeruginosins with molecular masses 602 Da (B), 618 Da, and 656 Da  
(A and B) were potential canditates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1:  LC-MS base peak ion chromatogram of a methanol extract from 
Microcystis CAWBG11 for the retention region of aeruginosin-like 
compounds. 
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The tandem mass spectral analysis of each compound confirmed all were 
aeruginosins as they produced diagnostic fragments commonly observed in 
aeruginosins115 such as m/z 70 (Arg fragment C4H8N
+), m/z 86 (Leu or Ile 
immonium ions), m/z 140 (Choi immonium ion) and m/z 250 (Hpla-Leu – CO + H) 
(Appendix B.5). There were several aeruginosins with the same molecular mass 
(461, 602 and 656 Da) but with different retention times.  
 
Table 2.1:  Molecular masses and retention times of aeruginosin analogues found 
in Microcystis CAWBG11. 
Compound Aeruginosin Mra 
(Da) 
RTb 
(min) 
Reference 
A 298B (11) 462.3 4.2 95 
B EI461B (15)  462.5 4.4 117 
C 602A (60) 602.3 5.0 115 
D 602B (61) 602.4 4.9 This study 
E 289A (6) 604.3 4.5 71 
F 618 (62) 618.2 4.6 This study 
G 656A (63) 656.3 5.2 This study 
H 656B (64) 656.3 5.4 This study 
a molecular mass rounded to one decimal place, b retention time,  
 
 
2.2.1 Characterisation of aeruginosins 298B (11) and EI461 (15) by 
tandem mass spectrometry. 
 
The MS/MS analysis of two ions with the same molecular mass; m/z 462 Da 
shared similar fragmentation patterns (Table 2.2; Appendix B.3).  
The fragment ions demonstrated that these compounds had an amino acid 
sequence of Hpla-Leu-Choi with NH2 at the C-terminus. This matches the 
structure of the previously reported aeruginosins 298B (11) and EI461(15).95,117  
It was noted that aeruginosins 298B (11) and EI461(15) were stereoisomers  
consisting of the same amino acid compositions but with different  
stereochemistry at the Hpla and the Choi moieties.95,117 This has also been  
reported for other aeruginosins; 89A/89B (12/13),95 KT608A/KT608B (23/24)21 
and 205A/205B (33/34)75 which might well explain why some of the aeruginosins 
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detected from Microcystis CAWBG11 have the same mass but different retention 
times. 
 
Table 2.2:  Assignment of fragment ions from tandem mass spectrometry for 
aeruginosins 298B (11) and EI461 (15). 
 
 
2.2.2 Characterisation of aeruginosin 602A (60) and 602B (61) by tandem 
mass spectrometry. 
 
The MS/MS spectrum of the ion with molecular mass m/z 603 (Figure 2.2) 
indicated that it was the known but incompletely characterised aeruginosin 602 
reported by Welker et al. (2006),115 as the fragment ions detected matched those 
reported previously. Also present was another compound with the same mass but 
a different retention time by reversed phase column chromatography (Table 2.1)  
 
Intensity 
 
 
 
 
 
 
 
 
 
 
Figure 2.2:  The tandem mass spectrum of aeruginosin 602A (60).Fragmentation 
was induced by matrix-assisted laser desorption/ionisation post-
source decay. 
Fragment Ion Assignment m/z for 298B (11) and EI461 (15) 
Hpla-Leu-Choi-NH2 – H2O + H 445 
Hpla-Leu-Choi + H 417 
Hpla -Leu + H 278 
Hpla-Leu – CO + H 250 
Hpla-OH + H 185 
Choi +H 167 
Choi immonium ion 140 
Leu immunion ion 86 
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This compound had identical MS/MS fragmentation pattern and therefore the two 
aeruginosins were designated as aeruginosins 602A (60) and 602B (61). 
Aeruginosin 602A (60) was previously characterised by MS/MS only. In this 
instance, a sufficient quantity of aeruginosin 602A (60) was purified in order to 
further characterise the compound by NMR spectroscopy and by amino acid 
analysis. An attempt to separate aeruginosin 602B (61) from other sample 
components by HPLC chromatography was not successful. 
 
2.2.1 Characterisation of aeruginosin 298A (6) by tandem mass 
spectrometry. 
 
The MS/MS spectrum of the m/z 605 ion (Figure 2.3) shared common fragments 
diagnostic of aeruginosins m/z; (86, 100, 140, 250 and 266). In addition to these, 
the fragment ions m/z 133 (Choi-Argol –NH2 + H), m/z 155 (Argol fragment) and 
m/z 100 (Argol fragment) indicated that the amino acid sequence for this 
compound was Hpla-Leu-Choi-Argol. An aeruginosin with the same amino acid 
sequence had been previously reported as 298A (6), due to limited information 
gathered on m/z 605, it is highly likely that this is the known aeruginosin 289A (6). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3:  Tandem mass spectrum of aeruginosin 298A (6). Fragmentation 
induced by matrix-assisted laser desorption/ionisation post-source 
decay. 
 
An attempt to isolate aeruginosin 298A (6) from other sample components was 
carried out using reversed-phase HPLC but this was unfortunately not successful. 
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2.2.2 Characterisation of aeruginosin 618 (62) by tandem mass 
spectrometry. 
 
Based on the matrix-assisted laser desorption/ionisation post-source decay 
(MALDI PSD) - MS/MS spectrum and the fragmentation patterns commonly 
observed in the presently characterised aeruginosins, a planar structure for 
aeruginosin 618 was proposed (Figure 2.4a). The main fragment ion (m/z 325) 
resulted from the loss of Leu-Hpla and NH3. Also observed was a Choi 
immonium ion (m/z 140) diagnostic for aeruginosins. The Arg y-ion (m/z 175) 
indicated that the C-terminus of this aeruginosin was Arg, a modification which 
has not been observed before. An ion series extending from m/z 175 confirmed 
that the amino acid sequence for aeruginosin 618 (62) was; Hpla-Leu-Choi-Arg 
(Figure 2.4).  
a) 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
 
Figure 2.4:  a) Proposed planar structure and b) the tandem mass spectrum of 
aeruginosin 618 (62). Fragmentation was induced by matrix- assisted 
laser desorption/ionisation post-source decay. 
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Unfortunately, the presence of phthalate plasticiser in the fractionated sample 
made the structural characterisation of aeruginosin 618 (62) by NMR 
spectroscopy too difficult to complete at the present time. 
 
2.2.3 Characterisation of aeruginosin 656A (63) and 656B (64) by tandem 
mass spectrometry. 
 
The MS/MS spectrum of aeruginosin 656A (63) was very similar to that of 
aerugisnosin 618 (62) as it contained m/z 70, 86 and 140. However the main 
fragmentation ion of 656A (63) was m/z 362 which results from the loss of Leu, 
Hpla and H2O + 2H (Table 2.3, Appendix B.2). The presence of an ion with 
molecular mass m/z 196 indicated that the C-terminus of 656A contained an extra 
38 Da compared to aeruginosin 618 (62). The composition of the ion m/z 196 
could not be further determined by tandem mass spectrometry at the present time. 
Based on the gathered MS/MS information, a planar structure for 656A (63) was 
proposed (Figure 2.5). 
 
Table 2.3:  Assignment of fragment ions from tandem mass spectrometry for 
aeruginosins 618 (62) and 656A (63). 
Fragment Ion Assignment m/z for 618 (62) 
 
m/z for 656A (63) 
M + H 619 657 
M – H2O + H 602  
M – Hpla + H 455 493 
M – Hpla – Leu + H 342 380 
M – Hpla – Leu – H2O + 2H  362 
M – Hpla – Leu – H2O + H 325  
Choi-Argol – CH3N2 – H2O + H 266  
Hpla-Leu – CO + H 250 250 
C-terma + C3H3O + H 229  
C-term + H 175 196 
C-term – NH2 + H 158 180 
Choi immonium ion 140 140 
Dehydrated Choi immonium ion  122 
C-term fragment (C5H10N3) 112  
Leu immonium ion 86 86 
C-term fragment (C4H8N+) 70 70 
a C-terminus with Arg for aeruginosin 618 (62), 196 Da for aeruginosin 656A (63). 
 
 43 
 
 
362.3
 
657.4
 
638.5
 
140.3
 
196.3
 
380.4
 
344.3
 
347.0
 
86.3
 
250.4
 
70.2
 
606.4
 
122.3
 
493.2
 
166.3
 
550.4
  
319.4
 
267.1
 
408.1
 
442.1
 
392.1
 
180.1
 
2000
 
4000
 
6000
 
 
100
 
200
 
300
 
400
 
500
 
600
 
700
 
m/z
 
Hpla  -  H (164 Da)Leu + H2O (131 Da)Choi - H ( 166 Da)196 Da
x10
4
Intensity
OH
OH
N
H
O
N
OH
O
O R
550  + H
493 + H 362 + H
196 + H
 
Figure 2.5:  a) Proposed planar structure and b) the tandem mass spectrum of 
aeruginosin 656A (63).Fragmentation induced by matrix-assisted 
laser desorption/ ionisation post-source decay. 
a) 
 
 
 
 
 
 
 
b)   
 
 
 
 
  
 
 
 
 
 
A compound, 656B (64) with the same mass as 656A (63) but with a different 
retention time on reversed-phase C18 chromatography was also detected in the 
LC-MS analysis of Microcystis CAWBG11. The LC-MS/MS fragmentation for 
this compound (Appendix B.2) was the same as that of aeruginosin 656A (63) 
suggesting that the two compounds have the same amino acid sequence but 
potentially differ by some stereochemical element.  
 
 
 Advanced Marfey’s Method of amino acid analysis of 656A (63), 656B 
(64) and 602A (60). 
 
The amino acid analyses of aeruginosins 656A (63), 656B (64) and 602A (60) 
indicated that the Leu residue in position two of each compound was in the 
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D-configuration (m/z 424; 28.7 min; Figure 2.6). The determination of the 
configuration of the amino acid present was possible by derivatising standard Leu 
with L- and D-1-difluoro-2,4-dinitrophenyl-5-leucine amide (FDLA) (Appendix 
C.2). It was not possible to determine the configuration of the Hpla, Choi and  
C-terminal amino acids during the period of this study due to time constraints.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6:  Advanced Marfey's method of amino acid analysis of hydrolysate of 
aeruginosins a) 656A (63), b) 656B (64) and c) 602A (60) with        
L-FDLA. 
 
 NMR spectroscopic characterisation of aeruginosin 602A (60). 
 
In the current study, a sufficient quantity of aeruginosin 602A (60) was isolated to 
enable structural characterisation by NMR spectroscopy. In a Rotating Frame 
Nuclear Overhauser Effect Spectroscopy (ROESY) spectrum (Appendix B.10) 
correlations confirmed the amino acid sequence determined during the MS/MS 
analysis (Hpla-H2 →Leu-H2; Leu-H3 → Choi-H7'; Choi-H3 → Argal-H2); 
Figure 2.7. Assignment of 1H and 13C NMR signals for 602A (60) (Table 2.4) was  
accomplished by interpretation of Correlation Spectroscopy (COSY), Total 
Correlation Spectroscopy (TOCSY), Heteronuclear Single Quantum Coherence 
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(HSQC) and Heteronuclear Multiple-Bond Correlation (HMBC) NMR 
experiments. 
 
 
 
 
 
Figure 2.7:  Proposed structure of aeruginosin 602A (60) with selected ROESY 
correlations (arrows). 
Table 2.4:  Nuclear magnetic resonance spectral data of 602A (60) in CD3OD. 
Position 
 
 
1H    
Multiplicitya 
(J in Hz) 13C COSY HMBC 
Hpla  1 -  174.5    
 
2 4.23  m 74.0  Hpla 3a, 3b Hpla-1, 4 
 
3a 2.98  dd (14.7, 4.8) 40.8  Hpla-2  
 
3b 2.82  m 
 
  
 
4 -  129.4    
 
5/9 6.68  m 116.1   Hpla-4, 7 
 
6/8 7.05  dd (8.68, 1.99) 131.9   Hpla-3, 4, 7 
 
7 -  157.4    
2-OH ndb     
Leu 1 -  nd   
 
2 4.67  t (3.6,1.4) 50.9  Leu-3  
 
3a 1.29 m 42.4  Leu-2, 4 Leu-4, 5 
 
3b 1.45 m 
 
  
 
4 1.31  m 26.1  Leu-5, 3  
 
5 0.91  m 22.1  Leu-4  
 
5' 0.88  m 23.9  Leu-4  
 
N-H nd  d 
 
  
Choi 1 -  nd   
 
2 4.43  t (8.2) 62.7  Choi-3 Choi-1,3 
 
3a 2.00 m 32.1    
 
3b 2.09  m 
 
  
 
3' 2.40  m 38.2  Choi-4a  
 
4a 1.58  m 20.3  Choi-5 Choi-3 
 
4b 1.60  s 
 
  
5 2.22  m 32.1  Choi-6  
 6 4.08  s 66.6  Choi-4, 5, 7 Choi-4, 7' 
 7a 2.82  m 34.5    
 7b 1.83  s    
 7' 4.24  m   56.6  Choi-7a  
Argal 1 5.35  d (3.2)   78.3    
 2 3.85  m   54.0  Argal-3  
 3a 2.12  m   31.7  Argal-4  
 3b 2.00  m    
 
4 1.56  m   27.1  Argal-5  
 1.63  m    
 
5 3.14  d (1.09)   42.6    
 3.20  d (1.27)    
 
6    -  nd   
 
2-NH nd   s 
 
  
1-OH   nd    
aMultiplicity of proton signal; m = multiplet, d = doublet, s = singlet, bnot detected. 
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The Hpla moiety of 602A (60) (Figure 2.8) gave rise to proton signals at, 2.82, 
2.98, 4.23, 6.68 and 7.05ppm. (Appendix B.5, Appendix B.6) The chemical shifts 
of the signals at 7.05 and 6.68 ppm were indicative of an aromatic ring. 
Integration of the signals showed that each signal was due to two protons, 
indicating that the ring was symmetrically substituted and that the H5/H9 and 
H6/H8 protons were in equivalent chemical environments. The 6.68 ppm signal 
was assigned as the H5/H9 protons due to the vicinal coupling to H6 (7.05 ppm) 
and long range coupling (4J) to the H3 methylene (2.82 and 2.98 ppm) and the 
7.05 ppm signal was assigned as the H6/H8 due to being coupled to H5 (8.68 Hz) 
and to H9 (1.99 Hz). 
a)   b) 
 
 
 
 
 
Figure 2.8:  a) The COSY and b) HMBC correlations within the Hpla moiety of 
aeruginosin 602A (60). 
 
The HMBC spectrum for 602A (60) (Appendix B.12) contained correlations from 
H6 to C3 (40.8 ppm), C4 (129.4 ppm), C5 (116.1 ppm) and C7 (157.3 ppm). 
Similar HMBC correlations were seen from H5 to C4 and C7. The HSQC 
spectrum (Appendix B.11) revealed that the protons attached to C3 were in two 
different chemical environments; 2.98 ppm (H3a) and 2.82 ppm (H3b) due to 
restricted rotation. The multiplicity of the H3a signal was a doublet of doublets 
due to germinal coupling to H3b (14.7 Hz) and vicinal coupling to H2 (4.23 Hz). 
The multiplet at H3b showed similar correlations to H3a and to H2 and could also 
experience long range coupling to H5 as indicated in the COSY spectrum 
(Appendix B.8). The chemical shift of H2 indicated the effect of the electron 
withdrawing hydroxyl group attached to it and the adjacent carbonyl group. The 
presence of the neighbouring carbonyl was indicated by HMBC correlations from 
H2 to C1 (74.5 ppm). 
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A correlation in the ROESY spectrum (Appendix B.10) from Hpla-H2 (4.23 ppm) 
to a one proton triplet at 4.67 ppm indicated connectivity with the second amino  
acid. The HSQC spectrum established that this proton signal correlated to a 
methine carbon at 50.9 ppm. The chemical shift of the proton signal (4.67 ppm) 
was typical of a methine adjacent to a carbonyl and an amide group. The 
multiplicity of the proton signal (triplet) indicated that a methylene group was 
adjacent, hence this was assigned as H2 of the Leu residue. 
 
Within the Leu moiety (Figure 2.9), H2 showed a COSY correlation to two non-
equivalent H3 protons (1.29 and 1.45 ppm). The HSQC spectrum indicated that 
these signals corresponded to the methylene carbon at 42.4 ppm. The two H3 
proton signals were both multiplets, each with an integral value of one proton. 
The COSY spectrum indicated that H3a (1.45 ppm) was coupled to H4 (1.31 
ppm), whilst the HSQC spectrum showed that H4 was attached to a methine 
carbon which resonated at 26.1 ppm. Correlations in the COSY and HMBC 
spectrum also supported this substructure (Figure 2.9). 
 
a) b) 
 
 
 
 
 
 
Figure 2.9:  a) The COSY and b) HMBC correlations within the Leucine residue 
of aeruginosin 602A (60). 
 
The Distortionless Enhancement by Polarisation Transfer (DEPT)-135 spectrum 
(Appendix B.7) indicated that there were two methyl carbons in the compound 
and these were assigned as C5 (22.1 ppm) and C5' (23.9 ppm) of the Leu residue. 
The HSQC spectrum revealed that the H5 and H5' protons resonated as multiplets 
at 0.91 and 0.88 ppm respectively. Whilst the H5 and H5' signals overlapped, 
integration of the spectral region revealed the six protons of the two methyl 
groups. The HMBC lacked correlations from H2 or H3 to the C1 of the Leu 
moiety; hence the chemical shift for C1 was not determined. 
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A correlation in the ROESY spectrum from Leu H3 (4.67 ppm) to a proton 
multiplet at 4.24 ppm yielded the connection to the Choi moiety. The HSQC 
spectrum indicated that the proton (4.24 ppm) was correlated to a methine carbon 
at 56.6 ppm. The DEPT-90/135 spectra indicated that the Choi moiety contained 
four methine carbons. The carbon signal at 56.6 ppm with an attached proton at 
4.24 ppm could represent either C2 or C7' as both carbons neighbour the -NR- 
group. However H2 would be more downfield as it is also next to a carbonyl 
group. The COSY spectrum indicated that H7' was coupled to a multiplet signal at  
2.82 ppm. 
 
a) b) 
 
 
 
 
 
 
Figure 2.10:  a) The COSY and b) HMBC correlations of the Choi moiety of 
602A (60). 
 
The HSQC spectrum indicated that the 2.82 ppm proton signal correlated to a 
methylene carbon which resonated at 34.5 ppm. It also revealed that the chemical 
shift of the other proton attached to it was a singlet at 1.83 ppm. The proton signal 
at 2.82 ppm also showed a COSY coupling to a signal at 4.08 ppm. The HSQC 
spectrum revealed that this singlet was correlated to a methine carbon at 66.6 ppm, 
the downfield chemical shift of which indicated the presence of the electron 
withdrawing group (OH) adjacent to it. This led to the assignment of C6 (66.6 
ppm), C7 (34.5 ppm) and C7' (56.6 ppm). In addition, the COSY and TOCSY 
(150 ms) spectra (Appendix B.8, Appendix B.9) showed correlations between H6 
(4.08 ppm) and H4a (1.60 ppm), H4b (1.58 ppm), H5a (2.24 ppm), H7a (1.89 ppm) 
and H7b (2.82 ppm). The COSY spectrum also contained a correlations from a 
triplet signal at 4.43 ppm (H2) to a signal at 2.40 ppm (H3') and to a multiplet 
signal at 2.00 ppm (H3a). The HSQC spectrum revealed that this proton triplet 
corresponded to a methine carbon (C2; 62.7 ppm). The HMBC spectrum 
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displayed a correlation from 4.43 ppm signal to a carbonyl group C1 (173.3 ppm). 
The correlations supported the substructure on Figure 2.10. 
 
A ROESY correlation from Choi-H2 to a multiplet signal at 3.85 ppm correlated 
to a carbon signal at 54.0 ppm (by HSQC), indicated connection to a signal at C2 
of the Argal moiety. The COSY spectrum showed a correlation from the H2 
proton signal to multiplet signals at 5.35 ppm, 2.12 ppm and 1.56 ppm and the 
HSQC spectrum indicated the corresponding carbons as C1 (78.3 ppm), C3 (3.17 
ppm) and C4 (27.1 ppm) respectively. 
 
a)  b) 
 
 
 
 
 
Figure 2.11:   a) The COSY and b) HMBC correlations within the Argininal 
moiety of 602A (60). 
 
In addition, the COSY spectrum contained a correlation from H3 (2.12 ppm) to a 
multiplet signal at 1.63 ppm (H4b) and to doublets at 3.14 ppm and 3.20 ppm. The 
downfield chemical shifts at 3.14 and 3.20 are typical chemical shifts of protons 
with an adjacent amine group; hence they were assigned as H5a and H5b and 
were correlated to a carbon signal at 42.6 ppm by the HSQC spectrum. The 
HMBC spectrum lacked any correlation from H5 to C6 so the chemical shift for 
C6 was not able to be determined at the present time. The correlation supported 
the substructure on Figure 2.11. 
 
It is possible that there were impurities present in the sample. There were 
indications of the presence of other solvents apart from water, CD3OD and HOD 
(3.31 ppm, 4.78 ppm). A proton singlet at 8.53 ppm was correlated to a carbon at 
170.5 ppm with a 1J coupling constant of 190 Hz, typical of a carbonyl proton 
from a formic acid or formate salt. Another carbon signal at 99.6 ppm did not 
theoretically fit into any of the carbon environments of the aeruginosin compound. 
However if the formate acid/salt was present than this could be a part of the salt as 
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it is a typical H-C(O)-O-CHR carbon. This formic acid/formate salt could have 
come from the formic acid used during isolation of the compound.15 The presence 
of these solvents peaks could contribute to overlap in the NMR spectra. 
 
 Future Work. 
 
Due to time constraints, a number of areas of interest remained unexplored but 
would form a basis for future research. Most of the aeruginosins detected are 
assumed to be stereoisomers of each other due to their different retention times 
but similar MS/MS fragmentation patterns. Identification of the structural 
differences in these will be very helpful for other researchers. 
 
Plasticiser is a common problem, especially when working with semi-purified and 
purified samples of organic extract. Development of an effective method to totally 
remove plasticiser from precious sample would be very useful. If that is 
achievable, then further structural characterisation of aeruginosins 618 (62) 
and 656A (63) would be possible. 
 
The structural characterisation and chemical properties of aeruginosin 602A (60) 
were not fully determined, so in order to fully elucidate the structure, further work 
is needed such as X-ray crystallography, biological activity testing and synthesis. 
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3 Chapter 3:  Microviridin Metabolites from Microcystis  
   CAWBG11. 
 
 Introduction 
Microviridins are a group of tricyclic depsipeptides produced by cyanobacteria,105 
comprised of either thirteen or fourteen amino acids, seven of which are 
conserved. They are initially produced on the ribosome as a linear peptide which 
is folded into a tricyclic structure by grasp-like ligase enzymes to form the two 
esters and one amide bond.110 The linkages are formed between the ω-carbonyl 
groups of Asp and Glu and ω-amino and hydroxyl groups of Lys and Ser or Thr 
respectively.112 Final maturation of the microviridin occurs with release of the 
leader peptide and acetylation of the N-terminus.110 Microviridins reported to date 
contain only L-amino acids118 and due to their ability to inhibits specific proteases, 
are of pharmacological relevance.113 
 
Four putative new microviridins were detected in Microcystis CAWBG11 with 
molecular masses 1778A (65) and 1778B (66), 1760 (67) and 1764 (68) (Figure 
3.1). They were separated and purified using size exclusion chromatography and 
RP HPLC (Appendix C.1,Table 3.1). The microviridin judged the most pure by 
HPLC, 1778A (65), was subjected to NMR spectroscopy and amino acid analysis 
to determine the structure of the compound. The tandem mass spectral and amino 
acid analyses of the three other microviridins 1778B (66), 1760 (67) and 1764 (68) 
were used to propose their putative structures. 
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Figure 3.1:  LC-MS base peak ion chromatogram of a methanol extract from 
Microcystis CAWBG11 for the retention region of microviridin-like 
compounds. 
 
Table 3.1:  Molecular masses and retention times of microviridin analogues found 
in Microcystis CAWBG11. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Compound Microviridin [M + 2H]2+ a Mr (Da)b RT(min)c 
A 1778A (65) 888.4 1778.6 6.8 
B 1778B (66) 888.3 1778.8 7.0 
C 1760 (67) 879.3 1760.6 7.1 
D 1764 (68) 881.3 1764.2 6.5 
adoubly charged ions to one decimal place, b molecular mass rounded to one decimal 
place and cretention time. 
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 Characterisation of microviridin 1778A (65).  
 
Based on the interpretation of the LC-MS/MS spectra, NMR spectroscopic and 
chemical analyses, a planar structure was proposed for microviridin 1778A (65) 
(Figure 3.2). The amino acids at positions one, two and three were assigned from 
the LC-MS/MS spectrum as glycine (Gly) and two Phe residues but the sequence 
could not be determined from NMR spectroscopy. In addition, LC-MS/MS 
spectra confirmed that the amino acid at position five was Met, as reported in 
microviridins D (53) and K (57).105, 112 The Tryptophan (Trp) was assumed to be 
at position eleven as is observed in almost all the known variants except for 
microviridins E (54) and F (55).105 The amino acids at positions thirteen and 
fourteen were assigned as Asp and Tyr respectively. 
 
 
 
 
 
Figure 3.2:  The proposed planar structure for microviridin 1778A (65). The 
amino acids X1, X2 and X3 are Phe (×2) and Gly with the sequence 
yet to be determined. 
 
3.2.1 Characterisation of microviridin 1778A (65) by tandem mass 
spectrometry. 
 
The LC-MS/MS analyses as in Figure 3.3 yielded partial information about the 
amino acid composition of microviridin 1778A (65). The loss of the 218 Da (Tyr–
OH) - y ion from the parent ion resulted in a fragment ion m/z 1559, an indication 
that the C-terminus was of Tyr. Similarly, the loss of Glu-Asp-Tyr-OH (418 Da) 
resulted in a fragment ion of m/z 1359, which could represent the last three amino 
acids at positions twelve to fourteen of the compound. The 147 Da loss in the 
higher mass region indicates the present of Lys (side chain) at position five while 
in the lower mass region an ion at m/z 147 Da (neutral loss) indicated the presence 
of 2 × Phe. The loss of 181 Da (Tyr +H2O) shows that there was a free hydroxyl 
group in the compound. The presence of Met in the compound was determined by 
the loss of 150 Da (y ion) and the loss 57 Da indicated the presence of Gly. 
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Figure 3.3:  The LC-MS/MS spectrum of doubly charged ion m/z 888.4 
(microviridin 1778A (65)). 
 
3.2.2 Advanced Marfey’s Method of amino acid analysis for 1778A (65). 
 
The presence and stereochemistry of many of the amino acids in microviridin 
1778A (65) were determined by Advanced Marfey’s amino acid analysis. The 
LC-MS analysis of the L-FDLA derivative of hydrolysed peptide (Appendix C.3) 
indicated: L-Asp (m/z 426; 14.6 min), L-Glu (m/z 440; 15.5 min), L-Lys (m/z 733; 
31.1 min), L-Phe (m/z 458; 23.9 min), L-Ser (m/z 398; 14.2 min), L-Pro (m/z 408; 
17.6 min), L-Thr (m/z 412; 13.9 min), L-Gly (m/z 368; 17.5 min) and L-Tyr (m/z 
474; 19.2 min). The identity and stereochemistry of the amino acids were 
determined by comparing standard amino acids derivatised with L-FDLA and 
analysed in the same manner (Appendix C.2). 
 
All of the detected amino acids were in the L-conformation as reported in the 
previously characterised microviridin variants. Among these were the conserved 
amino acids such as Lys, Thr, Tyr, Pro, Ser, Asp and Glu. The peak for the Phe 
derivative was as twice as intense as that of the other amino acids, which indicates 
that there were two Phe residues present in microviridin 1778A. It was not 
possible to determine the stereochemistry of Trp as it is degraded during the 
hydrolysis and there was no Met standard available at the time of the experiment 
to confirm the suggestion from the tandem mass spectral analysis. 
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3.2.3 NMR spectroscopic characterisation of microviridin 1778A (65).  
 
Analysis of COSY, HSQC, HMBC and 13C NMR spectra of 1778A (65) provided 
information about the sequence of amino acids in the compound (Table 3.2), 
however due to time constraints and a complex spectrum on an instrument of 
insufficient resolution, information about the order of the amino acids in 
microviridin 1778A (65) was restricted. Since CD3OD solvent was used, amide 
proton chemical shifts were not visible in the spectra. 
 
Table 3.2:  Nuclear magnetic resonance spectral data of microviridin 1778A (65) 
in CD3OD. 
Position 
 
1H    
Multiplicitya 
(J in Hz) 13C COSY HMBC 
Ac 1 
 
 172 
  
 2 1.93 s 22.2 
 
Ac-1 
Thr 1 
 
 170.6 
  
 2 4.31  d 58.6 Thr -3 Thr-1 
 3 4.12  m 67.0 Thr-4, 2 
 
 4 1.15  d 18.4 Thr-3 Thr-3,2 
Phe 1 ndb     
 2 nd     
 3 nd     
 4   155.9   
 5/9 6.99  d (8.0) 118.3 Phe-6,8 Phe-4 
 6/ 8 7.13  m 126.3 Phe-5,8,7  
 7 7.18  m 128.3   
Tyr 1 nd     
 2 nd     
 3 nd     
 4 
 
 136.9 
  
 5,9 7.05  d (8.8) 129.9 Thr-6,9 Thr-4 
 6,8 7.55  d (7.8) 118.1 Thr-5,9 Thr-7 
 7 
 
 155.9 
  
Trp 1 nd     
 2' 
 
 136.6 
  
 3' 7.08  s 118.6 Trp-4' Trp-2',9' 
 4' 7.33  D (8.8) 112.1 Trp-3',5' Trp-3' 
 5' 7.15  m 126.3 Trp-6',4' 
 
 6' 6.72  m 115.2 Tpr-7' Trp-5' 
 7' 6.68  d 114.8 
 
Trp-6',8' 
 8' 
 
 156.1 
  
 9' 
 
 
   
Asp 1   170.0   
 2 4.46  m 55.7 Asp-3 Asp-1 
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The DEPT-135 spectrum (Appendix C.5) indicated that there were two methyl 
carbons in the compound with signals at 22.2 ppm and 18.4 ppm. The HSQC 
spectrum (Appendix C.6) indicated that these methyl carbons correspond to a 
singlet at 1.93 ppm and a doublet at 1.12 ppm respectively and each integrated as 
three protons. The HMBC NMR spectrum (Appendix C.8) showed that the methyl 
carbon associated with the proton signal was attached to a quaternary carbon at 
172.0 ppm and no other correlations were detected, hence this was assigned as the 
acetyl group at the N-terminus. 
 
The other methyl would be expected to be due to H4 of the position four Thr, one 
of the conserved amino acids in the known microviridin variants. The multiplicity 
of the doublet signal indicated that the neighbouring carbon was a methine, which 
was confirmed by the COSY spectrum (Appendix C.7) as it contained a 
correlation to a multiplet signal at 4.12 ppm (H3). The chemical shift of H3 was 
typical of a methine proton with a hydroxyl group attached to it. In addition, the 
4.12 ppm multiplet was also coupled to a doublet at 4.31 ppm (H2) and the HSQC 
spectrum (Appendix C.6) indicated that these methine protons were attached to 
carbons which resonated at 67.0 ppm (C3) and 58.6 ppm (C2) respectively. The 
HMBC spectrum indicated that H2 was correlated to a quaternary carbon at 170.6 
ppm (C1). These correlations were indicated in the substructure on Figure 3.4. 
  
 
 
 
Figure 3.4:  The COSY (two headed arrow) and HMBC (one headed arrow) 
correlations within the threonine for microviridin 1778A (65). 
 
 3 3.06  m 38.4 Asp-2  
  2.84  m    
 4   172.3   
Lys 1   175.7   
 2 4.7  m 55.7   
 3 1.95 m 21.1  Lys-4 Lys-1 
 4 2.21 m 31.7 Lys-5  
 5 1.44 m 28.1 Lys-6  
 6 1.29  s 22.3 Lys-5  
a Multiplicity of proton signal; m = multiplet, d = doublet, s = singlet, b not detected. 
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The presence of aromatic rings in the microviridin was indicated by downfield 
signals in the 1H NMR spectrum (Appendix C.4). Close examination of the COSY 
and HMBC NMR spectra indicated correlations within the aromatic rings, 
enabling assignment of three aromatic amino acids; Tyr, Phe and Trp which were 
expected to contain two, three and five different proton environments respectively. 
However, correlations from the aromatic protons to the aliphatic protons were not 
able to be detected due to poor resolution in the HMBC experiment.  
 
From the COSY spectrum, within the aromatic ring of Tyr, a proton with a 
doublet signal at 7.55 ppm (7.8 Hz) was correlated to another doublet signal at 
7.05 ppm (8.8 Hz) as shown in Figure 3.5. The HSQC spectrum indicated that 
these protons were attached to C6/C8 (118.1 ppm) and C5/C9 (129.9 ppm) 
respectively. In addition, HMBC and DEPT-135 spectra showed that the methine 
protons of H6/H8 and H5/H9 showed correlations to quaternary carbons with 
chemical shifts of 155.9 ppm and 136.9 ppm respectively. The downfield 
chemical shift at 155.9 ppm was typical of a quaternary carbon with a hydroxyl 
group attached and hence was assigned as C7. The other quaternary carbon was 
then assigned as C4 (136.9 ppm). These correlations were indicated in the 
substructure Figure 3.5. The correlations from other parts of Tyr were not evident 
from the COSY and HMBC NMR spectra. 
 
 
 
 
 
 
 
Figure 3.5:  The COSY (two headed arrow) and HMBC (one headed arrow) 
correlations within the tyrosine aromatic ring for microviridin 1778A 
(65). 
 
The correlations between the three proton environments of the Phe aromatic ring 
were evident from the COSY spectrum; a doublet at 6.69 ppm (H5/H9), multiplet 
at 7.13 ppm (H6/H8) and multiplet at 7.18 ppm (H7) as indicated in the 
substructure Figure 3.6. The HSQC spectrum showed that these methine protons 
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corresponded to carbon signals at 118.4 ppm, 126.3 ppm and 128.3 ppm 
respectively. The HMBC indicated that the quaternary carbon at 155.9 ppm (C4) 
was adjacent to H5/H9. 
 
 
 
 
 
 
 
Figure 3.6:  The COSY (two headed arrow) and HMBC (one headed arrow) 
correlations within the phenylalanine aromatic ring for  
microviridin 1778A (65). 
 
The proton environments of the Trp ring was also determined to consist of a 
singlet at 7.08 ppm (H3'), a doublet at 7.33 ppm (H4'), multiplets at 7.25 ppm (H5') 
and 6.62 ppm (H6') and a doublet at 6.68 ppm (H7') from correlations in the 
COSY spectrum. The HSQC and DEPT-135 spectra identified the corresponding 
carbons of the above protons as methine carbons at chemical shifts of 118.6 ppm 
(C3'), 111.2 ppm (C4'), 126.3 ppm (C5') 115.2 ppm (C6') and 114.9 ppm (C7') 
respectively.  
 
 
 
 
 
 
 
 
Figure 3.7:   The COSY (two headed arrow) and HMBC (one headed arrow) 
correlations within the tryptophan aromatic ring for microviridin 
1778A (65). 
The HMBC spectrum indicated that one of the methine carbons (C7') was adjacent 
to a quaternary carbon at 156.1 ppm C8'. HMBC correlations to the other C2' and 
C9' were not clearly indicated in the HMBC spectrum and similarly no further 
correlation was observed from the protons of the aromatic ring to the methylene 
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protons at C3 and C2 of Tyr. These observed correlations supported the 
substructure (Figure 3.7). 
 
Several other amino acids were able to be assigned from the COSY and HMBC 
spectra but full confirmation of the identities of each was not possible. The 
presence of Lys was deduced by interpretation of correlations of four consecutive 
methylene protons and one methine proton from the COSY spectrum. The 
methine signal H2 (4.7 ppm) is coupled to a multiplet at 1.95 ppm (H3). This 
multiplet was further split by other multiplets at 2.21 ppm (H4) and 1.44 ppm (H5) 
and H5 was also coupled to a triplet at 1.29 ppm (H6). The HMBC spectrum 
indicated that H3 correlated to 175.7 ppm (C1) but was not clear enough to further 
confirm the connection suggested by the COSY spectrum to the rest of Lys 
residue. The HSQC spectrum facilitated the assignment of the corresponding 
methine and methylene carbons as 55.7 ppm (C2), 21.1 ppm (C3), 31.7 ppm (C4), 
28.1 ppm (C5) and 22.3 ppm (C6). The correlations supported the substructure 
depicted in Figure 3.8. 
 
 
 
 
 
 
 
Figure 3.8:  The COSY (two headed arrow) and HMBC (one headed arrow) 
correlations within the lysine residue for microviridin 1778A (65).   
 
Similarly, the correlations within the Asp residue were deduced from the COSY 
spectrum which indicated that the 4.46 ppm signal (H2) was correlated to the 3.06 
ppm (H3a) and 2.84 ppm (H3b) signals. The carbons to which each proton was 
attached were determined from the HSQC spectrum as 55.7 ppm (C2) and 38.4 
ppm (C3) respectively. The HMBC spectrum indicated that H2 was correlated to a 
quaternary carbon signal at 170.0 ppm (C1) while H3 correlated to another 
quaternary signal at 172.4 ppm (which could be Asp C4). These correlation 
indicated the substructure Figure 3.9. 
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Figure 3.9:  The COSY (two headed arrow) and HMBC (one headed arrow) 
correlations within the aspartic acid residue for microviridin 1778A 
(65). 
 
 
 Characterisation of microviridin 1778B (66). 
 
Based on the similarity in terms of LC-MS/MS and amino acid analyses of the 
microviridin congener to that of 1778A (65), a planar structure was proposed for 
1778B (66). The proposed structure for 1778B (66) was assumed to be very 
similar to that of 1778A (65) (Figure 3.10) but could differ in some 
stereochemical aspect which could cause them to elute at different times. 
Unfortunately the experimental results were not sufficiently clear to propose 
anything further. 
 
 
 
 
 
Figure 3.10:  The proposed planar structure for microviridin 1778B (66). The 
amino acids X1, X2 and X3 are Phe (×2) and Gly with the sequence 
yet to be determined. 
 
3.3.1 Characterisation of microviridin 1778B (66) by tandem mass 
spectrometry. 
 
The doubly charged ion at m/z 888.4 (microviridin 1778B (66)) was present in 
Microcystis CAWBG11. This compound had a MS/MS fragmentation pattern  
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(Figure 3.11) identical to that of microviridin 1778A (65) but eluted from a  
reversed-phase C18 HPLC column at a different retention time (Table 3.1).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11:  The LC-MS/MS spectrum of doubly charged ion m/z 888.4 
(microviridin 1778B (66). 
 
3.3.2 Advanced Marfey’s Method of amino acid analysis for microviridin 
1778B (66). 
 
The Advanced Marfey’s amino acid analysis of 1778B (66) indicated the presence 
of L-Asp (m/z 426; 14.6 min), D-Glu (m/z 440 ; 16.5min), L-Lys (m/z 733: 31.1 
min), L-Phe (m/z 458; 23.9 min),L-Ser (m/z 398; 14.2 min), L-Pro (m/z 408; 17.8 
min), L-Thr (m/z 412; 14.1 min) and L-Gly (m/z 368; 17.5 min) (Appendix C. 9). 
 
 Characterisation of microviridin 1760 (67). 
 
The fragment ions from the MS/MS spectrum of microviridin 1760 (67) were very 
similar to those of 1778A (65) and 1778B (65). This was an indication of a similar 
planar structure. However the molecular mass of microviridin 1760 (67) was 18 
Da less than that of the 1778A (65) and 1778B (65). An ester bond was 
established due to loss of 18 Da as indicated by the differences in molecular 
masses of 1778A (65) and 1760 (67) between the Thr and Asp as shown in  
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Figure 3.12. The amino acid analysis indicated the same amino acids present as 
per 1778A (65) and 1778B (65), hence a planar structure of microviridin 1760 
was established (Figure 3.12). 
 
 
 
 
 
Figure 3.12:  The proposed planar structure for microviridin 1760 (67). The 
amino acids X1, X2 and X3 are Phe (×2) and Gly with the sequence 
yet to be determined. 
 
3.4.1 Characterisation of microviridin 1760 (67) by tandem mass 
spectrometry 
 
The MS/MS spectrum of microviridin 1760 (67) (Figure 3.13) showed common 
fragmentation ions and fragment losses to that of microviridins 1778A (65) and 
1778B (65). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13:  The LC-MS/MS spectra of doubly charged ion m/z 879.3 
(microviridin 1760 (67)). 
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The major fragment ion of 1760 (67) was the fragment ion m/z 1212 which was 
also present in 1778A (65) and 1778B (66) and the molecular mass of 
microviridin 1760 (67) was 18 Da (H2O) less than that of microviridin 1778A (65) 
which indicated that it has one less ester bond at the position four Thr and position 
ten Asp. As observed in the known microviridins (Appendix A.2), the most 
common loss of 18 Da to form an ester linkage occurred at the position four Thr 
and the position ten Asp. The Glu at position twelve was observed to have been 
methylated during methanolysis and would result in loss of 32 Da (MeO + H) 
when formed an ester linkage to Ser at position nine. 
 
3.4.2 Advanced Marfey’s Method of amino acid analysis for microviridin 
1760 (67). 
 
The amino acid analysis of 1760 (67) indicated the presence of the same amino 
acids as in microviridin 1778A (65) and 1778B (66): L-Asp (m/z 426; 14.6 min), 
L-Glu (m/z 440 ; 15.6 min), L-Lys (m/z 733; 31.1 min), L-Phe (m/z 458; 23.9 min), 
L-Ser (m/z 398; 14.2 min), L-Pro ( m/z 408; 17.8min), Thr (m/z 412; 14.1 min) and 
L-Gly (m/z 368; 17.5min) (Appendix C.10). 
 
 Characterisation of microviridin 1764 (68). 
 
A planar proposed structure of microviridn 1764 (68) given in Figure 3.14 was 
based on the MS/MS data and amino acid analysis. The MS fragment ions 
indicated the presence of Lys, Phe, Trp (×2) and Thr. In addition the amino acid 
analysis indicated that the first three amino acids (X1-X3) were Phe, Ala and Gly 
but the sequence is yet to be determined. The amino acid at position five was a 
Trp, indicated by the LC-MS/MS and due to overall molecular mass; the acid 
residue at position thirteen was Glu. It was assumed that the two ester linkages 
were formed as there was not loss of water indicated in the LC-MS/MS spectra. 
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Figure 3.14:  The proposed planar structure for microviridin 1764 (68). 
 
 
3.5.1 Characterisation of microviridin 1764 (68) by tandem mass 
spectrometry. 
 
The LC-MS/MS spectrum of 1764 (68) showed different fragmentation ions from 
the three earlier compounds as seen in Figure 3.15. However, a similar loss of 147 
Da from the higher mass region and only one 147 Da loss in the lower mass 
region indicated the presence of Phe and Lys in the compound. The presence of 2 
× Trp was indicated by the loss of 162 Da and the loss of 101 Da could indicate 
the presence of Thr. There was no indication of the presence of Met as seen in the 
earlier microviridins. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15:  The LC-MS/MS spectrum of doubly charged ion m/z 881.3 
(microviridin 1764 (68)). 
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3.5.2 Advanced Marfey’s Method of amino acid analysis for microviridin 
1764 (68). 
 
The amino acid analysis of 1764 (68) indicated the presence of the majority of the 
amino acids present in the first three microviridins but with the additional of Ala: 
L-Ala (m/z 382; 18.0 min), L-Asp (m/z 426; 14.7 min), L-Glu (m/z 440; 15.2 min), 
L-Lys (m/z 733; 31.0 min), L-Phe (m/z 458; 24.0 min), L-Ser (m/z 398; 14.0 min), 
L-Pro (m/z 408; 17.4min), L-Thr (m/z 412; 13.9 min) and L-Gly (m/z 368; 17.5min) 
(Appendix C. 11). 
 
 
 Future Work 
The new microviridin variants detected were putatively characterised according to 
the partial information gathered. In order to fully characterise these metabolites, 
the isolation and characterisation of these variants needs to be completed and may 
require isolation and purification of further material to provide enough sample.  
 
To collect more structural information by NMR spectroscopy, a higher resolution 
NMR spectrometer was required to resolve the midfield methine and methylene 
signals. Alternatively, more information could be gathered if more time was 
invested in experiments which allow signal assignment using the present 
instrument including resolved HQSC and HMBC and selective TOSCY 
experiments. The experiments should be repeated with a non-exchangable solvent 
such as DMSO-d6 or acetone-d6, in order to gather information on connectivity of 
the amide protons. All of the amide protons were exchanged in CD3OD in the 
current work, making it difficult to deduce the amide protons in the compound. 
 
The stereochemistry of Trp needs to be determined which requires hydrolysis 
under different conditions in order to avoid the degradation of Trp. Similarly, the 
stereochemistry of Met could also be determined if a standard Met acid was 
available. 
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4 Chapter 4:  Experimental  
 Commonly Used Solvents and Solutions 
- MilliQ with sensitivity > 18MΩ.cm was purified on an E-Pure still 
(Barnstead). 
- Methanol for LH-20 / bench columns only (not HPLC) was drum-grade 
and distilled before use. 
 
Table 4.1:  Solvents and their sources that were commonly used in this research. 
Solvent Source 
Formic Acid (FA) Ajax Chemicals 
HPLC- grade acetonitrile (ACN) Honeywell International 
HPLC-grade Methanol (MeOH) Ajax Chemicals 
Methanol-d4 (CD3OD) Sigma-Aldrich 
Trifluoroacetic acid (TFA) Acros Organics 
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Table 4.2:   List of common solutions used in this research. 
 
Solutions Composition 
10% Formic Acid  11.4 mL of 88% formic acid (10%; v/v)  
- Make up to 100 mL with MilliQ water and filter 
(0.45 μm)  
LC-MS Solvent A 2% ACN + 0.1% FA 
- 5 mL of 10% FA (0.1%; v/v) 
- 10 mL of HPLC-grade ACN (2%; v/v) 
- Make up to 500 mL  with MilliQ water 
LC-MS Solvent B 98% ACN + 0.1% FA 
- 5 mL of 10% FA (0.1% ; v/v) 
- 5 mL of deionised water (2% ; v/v) 
- Make up to 500 mL with HPLC-grade ACN. 
LC-MS Solvent C 
(Column wash) 
60% HPLC-grade acetonitrile  in MilliQ water 
LC-MS Solvent D 
 (Needle wash) 
50%  HPLC-grade methanol in MilliQ water 
MALDI Matrix Solution  2:1:1 MeOH/ ACN / 0.1%TFA 
- 0.250 mL of MeOH (50%; v/v)  
- 0.125 mL of acetonitrile (25%; v/v)  
- 0.125 mL of 0.1% (v/v) TFA (0.025%; v/v)  
- Solution was used for one week then discarded and 
fresh solution prepared 
MALDI Wash Solution  0.100 mL of 1% (v/v) TFA (0.1%; v/v)  
0.900 mL of 11.1 mM NH4H2PO4 (10 mM)  
- Stored at 4 °C and discarded after one month  
Isocratic HPLC Solvent 60%  MeOH + 0.01% TFA in deionised water 
-600 mL HPLC-grade MeOH 
- 100 µL TFA 
-Make up to 1L with MilliQ water 
Gradient HPLC 
           Solvent A 
 
H2O + 0.05% TFA 
           Solvent B ACN + 0.05% TFA 
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 Commonly Used Experimental Techniques 
 
Centrifugation was carried out using an Eppendorf MiniSpin Plus centrifuge. 
Samples and solvents were sonicated at ambient temperature in an ultrasonic bath 
(Aqua, Barnstead International). Lyophilisation of samples was conducted using a 
FreeZone6 freeze-drier (Labconco). 
 
 Commonly Used Fractionation Techniques. 
All the fractions were collected in conical flasks and concentrated under vacuum 
using a rotary evaporator (Büchi) at 35ºC. Fractions were then resuspended in 
MeOH, transferred into a glass scintillation vial (21 mL) and dried down under a 
stream of nitrogen at 35ºC. 
 
4.3.1 Size Exclusion Chromatography  
Size exclusion column chromatography was conducted using LH-20 material 
(Sephadex LH-20, Pharmacia Fine Chemicals). The samples were dissolved in 
minimal MeOH, and then loaded onto the column head and eluted with 100% 
MeOH. 
 
4.3.2 Isocratic High Performance Liquid Chromatography. 
Isocratic HPLC was performed using HPLC pumps (Waters 515) arranged to 
deliver different volumes of solvent. The eluting compounds were detected by a  
Photodiode Array Detector (PDA; Waters 996, 200-400 nm). Repeated injections 
of sample (0.120 mL) were fractionated on a C18 column (Econosil C18 10-µ, 250 
× 10 mm; Alltech) using a mixture of 60% ACN and 60% MeOH + 0.01%TFA at 
a flow rate of 5 mL/min. 
 
4.3.3 Gradient High Performance Liquid Chromatography  
Gradient HPLC was performed using two HPLC pumps (Waters 515) controlled 
by Empower Pro (Waters). Eluting compounds were detected by a PDA detector; 
(200-400 nm; Waters 2996). Samples were dissolved in HPLC-grade MeOH (1.2 
mL) and syringe filtered (0.2 μm). Repeated injections of samples (100 μL) were 
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fractionated on a C18 HPLC column (Econosil C18 10-µm, 250 × 10 mm; Alltech 
using the H2O→ACN + 0.05% TFA gradient at a flow rate of 5 mL/min.  
 
 Characterisation Techniques Used. 
4.4.1 Liquid Chromatography Mass Spectrometry 
Samples were separated on an HPLC system (UltiMate 3000, Dionex) which was 
directly coupled to an electrospray ionisation (ESI)-ion trap mass spectrometer 
(AmaZon  X; Bruker Daltonics). The dual system was contolled by Hystar 
software (Bruker Daltonics). Samples (20 µL) were separated on a C18 column 
(Ascentis Express C18, 100 × 2.1 mm , 2.7-µm; Supleco Analytical) using the 
gradient outlined in Table 4.3 at a flow rate of  0.2 mL/min with a column 
temperature of 40 ºC. 
 
Table 4.3:   HPLC gradient for the LC-MS analysis. 
 
 
Tandem mass spectra were gathered using the protonated or doubly protonated 
ions of the desired compound. The m/z of the resulting fragment ions were 
recorded. Chromatograms and spectra were reviewed in DataAnalysis (Bruker 
Daltonics) where each chromatogram and spectrum was smoothed and peaks 
automatically selected using the Apex algorithm. 
 
4.4.2 Matrix-Assisted Laser Desorption/Ionisation-Time of Flight Mass 
Spectrometry  
Samples were analysed using an AutoFlex II MALDI-TOF mass spectrometer 
(Bruker Daltonics) operated with FlexControl (Bruker Daltonics). Samples were  
Time (min) %A 
(98:2 H2O:ACN)  
+ 0.1% FA 
%B 
(2:98 H2O:ACN)  
+ 0.1% FA 
0 90 10 
1 90 10 
13 0 100 
15 0 100 
16 90 10 
20 90 10 
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prepared for MALDI-TOF analysis by resuspending in MeOH and mixing of the 
sample (1 µL) with matrix solution (1 µL) on a MALDI target (600 µm anchorchip). 
Mass calibration was performed using a peptide calibration standard which was 
prepared in the same manner as the samples.  
 
4.4.3 Nuclear Magnetic Resonance Spectroscopy  
Nuclear magnetic resonance spectra were recorded on a Bruker AVIII-400 NMR 
spectrometer. Chemical shifts were determined at 300 ºK and are reported relative 
to the solvent signal (CD3OD; 
1H 3.31 ppm, 13C 49.15 ppm). Standard pulse 
sequences were used for HSQC, HMBC, COSY, TOCSY and ROESY 
experiments. TOCSY experiments were conducted with mixing times optimised 
for the detection of short, medium and long range couplings. HMBC spectra were 
acquired using parameter sets optimised for 2-3J 1H-13C correlations. 
 
4.4.4  Amino acid analysis. 
Semi-purified and purified aeruginosin and microviridin samples were subjected 
to amino acid analysis by the Advanced Marfey’s method.16, 94 The L- and 
 D-FDLA used was synthesised by Dr. Jonathan Puddick during the course of his 
research.15 
 
The sample was resuspended in MeOH and 100 µL was removed to a Reacti vial 
or boil-proof centrifuge tube and dried under a stream of nitrogen at 35 ºC. The 
dried sample was resuspended in 6M HCl (0.5 mL), sealed and incubated at 110 
ºC for 16 h. The HCl was removed at 35 ºC under a stream of nitrogen before the 
hydrolysate was resuspended in water (110 µL) and aliquoted into two 1.5 mL 
centrifuge tubes (50 µL each) to which 1M NaHCO3 (20 µL) and L- or D-FDLA 
(100 µL at 1% in MeOH) was added. The tube was then vortexed and incubated 
for 1 h at 40 ºC. The reaction was quenched using 1M HCl (20 µL), diluted with 
MeOH (810 µL), centrifuged (14,500 rpm, 5 min) and 980 µL was transferred 
into a septum-capped LC-vial. 
 
The resulting derivative was analysed by LC-MS. The derivatised hydrolysate (20 
µL) was separated on a C18 column (Econosil C18, 250 × 3.2 mm, 5-μm; Alltech) 
using the H2O→ACN gradient outlined in Table 4. 4 (600 μL/min; 40 °C). 
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Eluting derivatives were detected by ultraviolet absorption (250-500 nm) and ESI 
MS (m/z 300-500). Negative ions were assessed using a capillary voltage of 3.5 
kV and a nebuliser pressure of 1.5 bar.  
 
Table 4. 4:   HPLC gradient for the Advanced Marfey’s method of amino acid 
analysis. 
 
4.4.5 Assessment of the Fraction Composition  
 
Sample fractions were assessed using LC-MS. Sample was resuspended 
in HPLC-grade MeOH (500 μL) and an aliquot (5 μL) was syringe filtered (0.2 
μm) into a septum-capped LC vial. The filter and syringe were then washed with 
50% HPLC-grade MeOH (995 μL; v/v). Negative ions were assessed over a 100-
2,000 m/z range and the resulting ion-chromatograms were integrated using 
QuantAnalysis (Bruker Daltonics). 
 
 
 
 
 
 
 
Time 
(min) 
%A 
(98:2 H2O/ACN 
+ 0.1% Formic Acid) 
%B 
(2:98 H2O/ACN 
+ 0.1% Formic Acid) 
0 75 25 
1 75 25 
31 35 65 
33 0 100 
35 0 100 
38 75 25 
45 75 25 
 72 
 
 Work Described in Chapter 2 
4.5.1 Isolation of aeruginosin compounds. 
Samples were isolated via a series of chromatography columns as in                     
Appendix C.1. The sample was dissolved in MeOH (0.6 mL) and loaded straight  
onto an LH-20 column. The vials were rinsed with distilled water (0.3 mL) and     
the rinsings were loaded onto the column head. Fractions were eluted with 100%  
MeOH, concentrated down by rotary evaporation and dried under a stream of  
nitrogen gas at 35 ºC. They were assessed by LC-MS using the protocol described
 in Section 4.4.1. 
 
4.5.2 Solid Phase extraction of aeruginosin 656A (63). 
Solid-phase clean-up was performed using a glass Pasteur pipette lightly plugged 
with cotton wool and filled with C18 material (500 mg; YMC-gel ODS-A; YMC). The 
solid-phase clean up column was primed with 100% MeOH + 0.01%TFA 
then equilibrated with 20% MeOH + 0.01% TFA (5 mL). Sample was resuspended in 
20% MeOH (0.3 mL 20% MeOH + 0.01% TFA). The sample was loaded onto the 
solid-phase column and allowed to flow through. It was washed with 20%, 40%, 60% 
× 2 and 100% MeOH + 0.01% TFA (5 mL each) and each fraction was collected 
(fractions 1-5) in scintillation vials. Samples were rotary evaporated and dried under 
a stream of nitrogen gas at 35 ºC and were assessed by LC-MS using the protocol 
described in Section 4.4.1. 
 
4.5.3 Isocratic HPLC of aeruginosins. 
Sample (11 mg) was suspended in HPLC-grade MeOH (250 µL) and was diluted 
with MeOH + 0.01% TFA (250 µL). It was then filtered into another scintillation 
vial through a syringe filter (0.2 µm). The original flask was rinsed with MeOH + 
0.01% TFA (4 × 125 µL) and the rinsings were filtered into the solution making 
up a total of 1 mL. The solution was then subjected to isocratic HPLC 
fractionation using the protocol described in Section 4.3.2 with a 2 mL injection 
loop. Repeated isocratic HPLC was carried out with the same protocol but with 55% 
MeOH + 0.01% TFA as solvent. The fractions were assessed with LC-MS using 
the protocol described in Section 4.4.1. 
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4.5.4 NMR characterisation of Aeruginosin 602A (60). 
Sample was vacuum dried for at least two hours to minimise the presence of water 
in the compound. It was then dissolved in CD3OD, transferred into the NMR tube 
and several experiments were conducted using a Broadband Inverse Probe and the 
protocol described in Section 4.4.3. 
4.5.5 Amino acid analysis of aeruginosin-like compounds. 
The chemical analysis of each aeruginosin compound was determined using the 
protocol described in Section 4.4.4. 
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 Work Described in Chapter 3 
4.6.1 Isolation of microviridin-like compounds by LC-MS. 
Sample was isolated via a series of chromatography columns as in Appendix B.1. 
The sample was dissolved in methanol (0.6 mL) and a few drops of deionised 
water and loaded onto the head of an LH-20 column. The flask was rinsed with 
distilled water (0.3 mL) and the rinsings loaded onto the column. The column was 
eluted with 100% MeOH. The collected fractions were concentrated by rotary 
evaporation and dried under a stream of nitrogen gas at 35 ºC and assessed with 
LC-MS using the protocol described in Section 4.4.1. 
 
4.6.2 Gradient HPLC  
Sample was resuspended in HPLC-grade  MeOH (250 µL) and diluted with  water 
+ 0.05% TFA (250 µL) then filtered into a scintillation vial through a syringe 
filter (0.2 µm). The vial was rinsed with water + 0.05% TFA (4 × 150 µL) and the 
rinsings filtered. The solution was subjected to gradient HPLC with a 200 µL 
injection loop using the protocol described in Section 4.3.3 and the gradient 
profile in Table 4.5.  
 
Table 4.5:  HPLC gradient for fractionation of microviridin compounds. 
Time 
(min) 
%A 
H2O + 0.05% TFA 
%B 
ACN + 0.05% TFA 
0 90 10 
3 90 10 
6 69 31 
26 69 31 
33 0 100 
36 0 100 
37 90 10 
40 90 10 
 
Fractions were analysed by LC-MS using the protocol described in Section 4.4.1. 
 
4.6.3 Amino acid analysis of microviridin-like compounds. 
The chemical analysis of each microviridin compound was determined using the 
protocol described in Section 4.4.4. 
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5 Appendices 
Appendix A.1:  Amino acid sequence and biological activities of the known aeruginosins. 
 
 
 
 
Aeruginosina Mrb 
1: Hpla 
2: Hydrophobic 
amino acid 
3: Choi 
4: Arginine 
derivative 
Biological Activitiesg Reference 
X1 R1 X2 R2 R3 R4 
298A (6) 604.4 H OH H Leu OH Argol THB, TRP 71 
98A (7) 688.4 Cl OH H allo-Ile OSO3H Agma TRP, THB, PLM 82 
98B (8) 654.4 H OH H allo-Ile OSO3H Agma TRP, THB, PLM 82 
98C (9) 732.2 Br OH H allo-Ile OSO3H Agma TRP, THB, PLM 83 
101 (10) 722.2 Cl H Cl allo-Ile OSO3H Agma TRP, THB, PLM 83 
298B (11) 461.2 H OH H Leu OH H2 TRP, THB, PLM, PAP 83 
89A (12) 716.2 Cl OSO3H H Leu OH Argal (2S) TRP, THB, PLM, PAP 83 
89B (13) 716.2 Cl OSO3H H Leu OH Argal(1S,2R) TRP, THB, PLM, PAP 83 
SF608 (14) 608.3 H OH H L-Phe OH Agma TRP 79 
EI461 (15) 461.2 H OH H Leu OH H2 TRP 117 
KY642 (16) 643.3 Cl OH Cl Ile OH Agma TRP 85 
KY608 (17) 643.3 Cl OH H Ile OH Agma TRP 85 
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GE686 (18) 689.2 Cl OH Br allo-Ile OH Agma TRP, THB 72 
GE730 (19) 733.2 Br OH Br allo-Ile OH Agma TRP, THB 72 
GE766 (20) 768.2 Cl OH Br allo-Ile OSO3H Agma TRP, THB 72 
GE810 (21) 810.1 Br OH Br allo-Ile OSO3H Agma TRP, THB 72 
GE642 (22) 643.3 Cl OH Cl Leu OH Agma TRP, THB 72 
KT608A (23) 608.3 H OH H Phe OH Agma TRP 21 
KT608B (24) 608.3 H OH H Phe OH Agma TRP 21 
KT650 (25) 650.3 H OH H Phe OH Agma TRP 21 
KT554 (26) 554.3 H OH H Leu H Agma TRP 21 
GH553 (27) 553.2 H OH H Tyr CO2CH3 H2 TRP 21 
IN608 (28) 608.3 Cl OH H Leu OH Agma TRP 86 
IN652 (29) 652.3 Br OH H Leu OH Agma TRP 86 
102A (30) 732.3 H OSO3H H Tyr OH L-Argal THB, TRP, PLM 73 
102B (31) 732.3 H OSO3H H Tyr OH D-Argal THB, TRP, PLM 73 
103A (32) 680.4 H OH H Tyr OH Aeap THB 87 
205A (33) 804.3 H H H D-Xyl-HLeu (2R,3S) Cl Agma TRP, THB 75 
205B (34) 804.3 H H H D-Xyl-HLeu (2S,3R) Cl Agma TRP, THB 75 
Oscillarin (36)  612.2 H H H Phe OH Adc TRP, THB 90 
NAL2 (37) 587.2 Butanoic acid 
Decanoic acid 
Tyr OH Argol  76 
NOL6 (38) 589.4 Tyr O-pentose Argol  76 
Aer856 (39) 865.4 H OH H Leu ManA, HA Agma  91 
DysA (40) 632.1 O-Me-O'-SO3Hc Leu OH Adc THB 78 
Cl-DysAd,e (41) 666.5 O-Me-O'-SO3Hc Cleu OH Adc THB 93 
Dys Bd,e,f (42) 780.3 O-Me-O'-SO3Hc Val OC6H6O4 Adc THB 77 
Dys Cd,e (43) 618.2 O-Me-O'-SO3Hc Val OH Adc THB 77 
Dys Dd,e (44) 539.3 O-Me-O'-Hc Val OH Adc THB 77 
a Order of aeruginosins according to aeruginosin 298A, b molar mass to one decimal place, c glyceric acid instead of Hpla, dCcoi instead of Choi, ePlas instead of 
Hpla,  fDysinosin, gThrombin, Trypsin, Plasmin, Papain. 
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Appendix A.2:  Amino acid sequence of the known microviridins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Microviridin Mra 
Sequence of amino acidsb 
References 
R 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
A (45) 1728.7 Acc Try  Gly  Gly Thr Phe Lys Tyr Pro Ser Asp Trp Glu Glu Tyr  104 
B (46) 1722.7 Ac Phe Gly Thr  Thr Leu Lys Tyr  Pro Ser Asp Trp Glu  Glu Tyr 102 
C (47) 1754.8 Ac Phe Gly Thr Thr Leu Lys Tyr Pro Ser-OH Asp Trp Glu-OMe Glu Tyr 102 
J (48) 1683.7 Ac  Ile Ser  Thr Arg Lys Tyr Pro Ser  Asp Trp  Glu  Glu  Trp  101 
SD 1684 (49) 1684.7 Ac  Thr Ala Thr-OH Arg Lys Tyr Pro Ser Asp-OH Trp Glu-OMe Has Tyr 103 
SD 1634 (50) 1634.7 Ac  Thr Ala Thr Arg Lys Tyr Pro Ser Asp Trp Glu Has Tyr 103 
SD 1652 (51) 1652.7 Ac  Thr Ala Thr-OH Arg Lys Tyr Pro Ser Asp-OH Trp Glu Has Tyr 103 
L (52) 1684.9 Ac Tyr Gly Gly Thr Phe Lys Tyr Pro Ser Asp Trp Glu Glu Tyr 100 
D (53) 1801.7 Ac Tyr Gly Asn Thr Met Lys Tyr Pro Ser-OH Asp Trp Glu-OMe Glu Tyr 105 
E (54) 1664.7 Ac  Phe Ser Thr Tyr Lys Tyr Pro Ser-OH Asp Phe Glu-OMe Asp Phe 105 
F (55) 1682.7 Ac  Phe Ser  Thr-OH Tyr Lys Tyr Pro Ser-OH Asp-OH Ph Glu-OMe Asp Phe 105 
I (56) 1764.7 Ac Tyr Pro Thr Thr Leu Lys Tyr Pro  Ser Asp Trp Glu Asp Tyr 107 
K (57) 1769.7 Ac Tyr Gly Asn Thr Met Lys Tyr Pro Ser Asp Trp Glu Glu Tyr 109 
G (58) 1805.8 Ac Tyr Pro Gln Thr Leu Lys Tyr Pro Ser Asp Trp Glu Glu  Tyr 108 
H (59) 1837.8 Ac Tyr Pro Gln Thr Leu Lys Tyr Pro Ser-OH Asp Trp Glu-OMe Glu  Tyr 108 
a molar mass to one decimal place, bsequence of amino acids according to microviridin A, cacetic acid  
 R      1        2       3       4      5        6       7        8       9      10     11     12     13      14 
Ac - Tyr - Gly - Gly - Thr - Phe - Lys - Tyr - Pro - Ser - Asp - Trp - Glu - Asp - Tyr  
         Phe   Ile    Asn            Leu                      Phe            Glu    Phe 
                  Phe  Gln             Met 
                  Pro   Ser     Tyr                       ε-N  
     Thr   Ala                             O   
              Thr             Arg                                            O 
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Appendix B.1:  Separation tree for fractionation of aeruginosin metabolites from Microcystis species CAWBG11. 
 
                                   Methanol extract with aeruginosins 298B (11), EI461 (15) and 656 (14.0 mg)                    Methanol extract with aeruginosin EI461 (15) and 656 (25.2 mg) 
a)  
 LH-20 Column (30 mg) 
      
 
       SK1-034    01     02 03         04          05          06         07         08          09           10           11          12          13          14          15           16           17         18                   LH-20 Column (30 mg) 
      Mass (mg)  0.6         2.3 3.4        3.4           5.9         2.8        2.1        2.4        2.9           2.7          2.2         2.1          2.8         0.9         2.3          3.3         3.5         2.8 
 
  
 LH-20 Column (30 mg)           Aeruginosins 298B (11) and EI461 (15) 
    
      
      SK1-042     01           02       03         04          05          06         07         08          09           10           11          12          13          14          15           16           17         18 
     Mass  (mg)  1.1         2.8       3.2        3.2        3.3         1.7        3.5        2.7         4.8           3.0          2.3         4.3         2.6         1.2         3.0          4.6         2.8         1.8 
 
                                                                                                          
                  LH-20 Column (30 mg)                       Aeruginosin EI461 (15) 
 
 
     SK1-056      01          02        03         04          05          06         07         08          09           10           11          12    
    Mass (mg)   1.3         0.4        1.3        3.6        4.2         4.3        1.5        2.1        5.3           5.3          3.8         2.9              
 
                                                                                                        LH-20 Column (30 mg) 
           
                                                                             SK1-142       01        02         03         04          05          06         07         08          09           10           11          12    
                 Mass (mg)   0.3         0.4         0.3        0.2         2.1         2.0        2.7        2.9        4.2          1.1          0.2         0.4              
 
 Isocratic HPLC 
 
           SK1-149       01         02          03          04           05          06         07         08          09           10           11          12    
                              Mass (mg)   1.6         1.8         1.2        1.7           0.6         0.9        3.8        2.8         2.5           2.4          1.5        1.4              
 
                                                                                                                                                                   Solid Phase Clean-up 
                                                                                                                                                                                                                                       Aeruginosin 656B (64) 
               SK2-031      01         02          03          04         05           
                                                                                       Mass (mg)   1.9        1.3         0.4        0.6        2.9                      
 
              Aeruginosin 656A (63) 
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b)                                                                 Semi Purified Methanol extract with aeruginosins 618 (62), 602B (61) and 298A (6) (11 mg) 
       
        Gradient HPLC 
 
   
        SK1-104      01         02            03         04          05          06         07         08          09                                          
                                 Mass (mg)   2.0        1.2         1.8         3.0          2.5         2.8         3.5        1.2         1.2            
 
     Aeruginosin 618 (62) Gradient HPLC 
                                                            
         
             SK1-104       01         02            03         04          05          06         07         08          09        10         11  
            Mass (mg)    0.6        0.9          0.5         0.4         1.4         1.3        2.9        1.2         1.8       1.7        0.6 
                            
 
                 Aeruginosins 602B (61) and 298A (6) 
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Appendix B.2:  The LC-MS/MS spectrum of a) aeruginosin 656A (63) and b) 
656B (64). 
 
a) 
 
 
 
 
 
 
 
 
 
b) 
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Appendix B.3:  Tandem mass spectrum of aeruginosin a) 298B (11) and b) 
EI461B (15). Fragmentation was induced by matrix-assisted laser 
desorption post-source decay. 
 
a)  
 
 
 
 
 
 
 
 
 
 
 
 
b) 
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Appendix B.4:  Tandem mass spectrum of aeruginosins a) 602A (60) b) 298A (6)  
c) 618 (62) and d) 656A (63). 
 
a) 
 
 
 
 
b) 
 
 
 
 
c) 
 
 
 
 
d) 
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Appendix B.5:  Downfield region of the 1H NMR spectrum of aeruginosin 602A 
(60) in CD3OD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix B.6:  Upfield region of the 1H NMR spectrum of aeruginosin 602A (60) 
in CD3OD. 
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Appendix B.7:  Spectra for a) 13C NMR, b) DEPT-135 and c) DEPT-90 of 
aeruginosin 602A (60) in CD3OD. 
 
a) 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
c) 
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Appendix B.8:  COSY NMR spectrum of aeruginosin 602A (60) in CD3OD 
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Appendix B.9:  TOCSY (150 ms) NMR spectrum of aeruginosin 602A (60) in CD3OD. 
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Appendix B.10:  ROESY NMR spectrum of aeruginosin 602A (60) in CD3OD. 
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Appendix B.11:  HSQC NMR spectrum of aeruginosin 602A (60) in CD3OD. 
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Appendix B.12:  HMBC NMR spectrum of aeruginosin 602A (60) in CD3OD. 
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Appendix C.1:  Separation tree for fractionation of microviridin metabolites from Microcystis species CAWBG11. 
 
 
Methanol extract with microviridin compounds (30 mg) 
  
         LH-20 Column (30 mg) 
        
                   SK1-008        01         02          03          04          05          06         07         08          09           10           11          12          13          14          15           16           17         18                    
                       Mass (mg)    1.3        2.2           2.7        4.1        7.1          6.4        5.2        5.1        5.4           4.1          3.0         1.6         2.9         1.0         1.4          6.0          3.1         5.3 
 
                                                                                  
                                                                LH-20 Column (30 mg) 
                
 
  SK1-042      01          02          03          04          05          06         07         08          09           10           11          12          13          14          15           16           17         18 
                              Mass (mg)  1.7         0.4          1.9         3.1        2.0         1.7        3.8        3.8         3.9           2.9          1.3         0.3         2.6         2.1         0.6          0.6          0.1        0.1 
 
 
                                                                                                       
                                                                                                                                                                       Gradient HPLC    
 
                                         
                                         SK2-036      01          02          03          04          05          06         07         08          09           10           11          12          13          14          15            
                                            Mass (mg)   3.1         1.9         2.4         1.8         2.0         2.3        1.9        2.6         2.3           1.2         1.4         1.5        2.0         3.4         1.0           
 
 
                        Microviridins:      1764 (68)      1778A (65)              1778B (66)              1760 (67) 
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Appendix C.2:  Extracted ion chromatograms from Advanced Marfey's amino 
acid analysis using a) L-FDLA and b) D-FDLA standard amino 
acid.  
 
a) b) 
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Appendix C.3:   Extracted ion chromatograms from Advanced Marfey's amino 
acid analysis using a) L-FDLA and b) D-FDLA for 1778A (65). 
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Appendix C.4:   The 1H NMR spectrum a) downfield region and b) upfield 
region of microviridin 1778A (65) in CD3OD. 
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Appendix C.5:  a) The DEPT-135 and b) 13C NMR spectrum of microviridin 1778A (65) in CD3OD. 
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Appendix C.6:  The HSQC NMR spectrum of microviridin 1778A (65) in CD3OD. 
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Appendix C.7:  The COSY NMR spectrum of microviridin 1778A (65) in CD3OD. 
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Appendix C.8:  The HMBC NMR spectrum of microviridin 1778A (65) in CD3OD. 
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Appendix C. 9:  Extracted ion chromatograms from Advanced Marfey's amino 
acid analysis using a) L-FDLA and b) D-FDLA for 1778B (66). 
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Appendix C.10:  Extracted ion chromatograms from Advanced Marfey's amino 
acid analysis using a) L-FDLA and b) D-FDLA for 1760 (67). 
a)        b) 
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Appendix C. 11:  Extracted ion chromatograms from Advanced Marfey's amino 
acid analysis using a) L-FDLA and b) D-FDLA for 1764 (68). 
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